Introduction {#sec1}
============

Because of the emergence and spread of multidrug resistant microorganisms and pathogenic bacterial infections, novel chemotype antibacterial agents demonstrating distinct modes of action from existing antibiotics are urgently needed. Natural products are known as rich sources of bioactive molecules and chemical diversity and have thus provided invaluable chemical scaffolds as well as served as an inspiration toward antibacterial drug discovery and development.^[@ref1]−[@ref4]^ In this context, synthesis and evaluation of natural-product-inspired compound libraries represent an attractive approach for discovering novel antibacterial agents.^[@ref5]^

Flavonoids are a large family of polyphenolic phytochemicals, which widely exist in the plant kingdom.^[@ref6]^ As such, flavonoids have been the focus of numerous basic biomedical research as well as clinical investigation.^[@ref7],[@ref8]^ As examples, high dietary intake of flavonoids may offer potential to reduce the risk of various cancers according to a number of epidemiological studies.^[@ref9]−[@ref13]^ In addition, flavonoids have been reported to display a broad spectrum of pharmacological activities, such as antimicrobial,^[@ref14]−[@ref16]^ anti-inflammatory,^[@ref17],[@ref18]^ cancer preventive^[@ref19],[@ref20]^ and anticancer,^[@ref21],[@ref22]^ and antioxidant activities.^[@ref23],[@ref24]^ It is also noteworthy that some widely investigated flavonoids, such as flavone acetic acid (FAA),^[@ref25]^ flavopiridol,^[@ref26]−[@ref28]^ silibinin (silybin),^[@ref29],[@ref30]^ and quercetin^[@ref31]^ and its derivatives^[@ref32]^ (Figure [1](#fig1){ref-type="fig"}), have progressed to various stages of clinical trials.^[@ref33]^ In this regard, plant-derived phytochemicals including chemically modified flavonoids and derivatives continue to attract great interest in the development of novel antibiotics.^[@ref34]^

![Skeleton structures of chalcones, 4-chromanones, and representative structures of naturally occurring flavonoids including abyssinone II and olympicin A.](jm-2014-00853v_0002){#fig1}

Furthermore, chalcones (1,3-diaryl-2-propen-1-ones), one subclass of structural analogues of flavonoids, have been reported to exhibit diverse biological activities,^[@ref35]−[@ref38]^ in which the enone functional group and the 2′-hydroxy group constitute important structural motifs for antibiotic activity. From a chemistry point of view, chalcones and 4-chromanones are structurally related, and 2′-hydroxychalcones serve as important synthetic precursors for the synthesis of 4-chromanones following an intramolecular conjugate addition of the phenol on the α,β-unsaturated system.^[@ref39]^ Notably, the 4-chromanone derivatives containing an aromatic substituent at the 2-position, so-called flavanones, have been identified as an important class of bioactive heterocycles.^[@ref40]−[@ref42]^

As a result of our longstanding interest in developing natural-product-inspired new antibacterial agents, we recently reported the identification of abyssinone II as a promising antibacterial lead by screening a focused flavonoid and resveratrol library.^[@ref43]^ In addition, olympicin A, a member of the natural acylphloroglucinol chemical class, was recently isolated from the plant *Hypericum olympicum* and reported to exhibit potent antibacterial activity against a panel of multidrug-resistant (MDR) strains of clinically relevant *Staphylococcus aureus*, with minimum inhibitory concentration (MIC) values ranging from 0.5 to 1 μg/mL.^[@ref44],[@ref45]^ Very recently, we have shown that synthetic olympicin A also exhibited good activity against *Clostridium difficile* (MIC = 1--2 μg/mL).^[@ref46]^ Inspired by the antibacterial activity of the natural products abyssinone II and olympicin A, in this work we employed the 4-chromanone and chalcone structural scaffolds as chemical starting points to design and synthesize chemically modified flavonoid analogues. Subsequently, several series of structurally related flavonoids were synthesized and evaluated in vitro against a broad set of bacterial pathogens and a detailed structure--activity relationship (SAR) has been obtained. Furthermore, the antibacterial basis of promising lead compounds and their ability to inhibit bacterial topoisomerases such as DNA gyrase or topo IV have also been examined.

Results and Discussion {#sec2}
======================

Synthesis of Olympicin A and Derivatives {#sec2.1}
----------------------------------------

The isolation and chemical synthesis of olympicin A (**2a**) was originally reported by Shiu et al., and its synthesis involved a four-step reaction sequence. However, the overall yield was only 3.3% from **1a**.^[@ref44]^ To improve the reaction efficiency and develop a modular synthesis toward olympicin A and derivatives, we evaluated diverse protecting schemes including the *tert*-butyldimethylsilyl (TBDMS), the base-stable methoxymethyl (MOM), and the *p*-toluenesulfonyl (Ts) groups and developed an improved synthesis of **2a** by using the Ts protecting strategy, improving the overall yield to 40% from **1a** (Scheme [1](#sch1){ref-type="scheme"}). In particular, we found that the reported low yield may be largely due to the instability of the TBDMS protecting group under basic reaction conditions (K~2~CO~3~, 80 °C) when introducing the geranyl group. To address this, the base-stable MOM group was next applied instead of TBDMS. Following the O-geranylation reaction, it was found that **2a** decomposed during the deprotection of the MOM groups because of the instability of *O*-geranyl group under the acidic condition, and the deprotected **1a** was recovered from the reaction. Subsequently the Ts group was used to protect the hydroxy group,^[@ref47]^ and only the tris(tosylate) **1b** was obtained as the major product because of the lack of selectivity of the Ts group under the reaction condition. Nevertheless, we found that the tosylate group at the 2-position of **1b** was very labile, and the geranyl group could be selectively introduced with sodium hydride as the base. Final removal of the Ts group was performed with excess sodium methoxide in methanol under reflux^[@ref48]^ to afford the chiral olympicin A (**2a**). The spectroscopic data of our synthetic olympicin A were in good agreement with those of the natural product.^[@ref44]^ For comparison, the racemic olympicin A (**2b**) was also synthesized under the same conditions to study the potential effect of stereochemistry on antibacterial property.

![Improved Synthesis of Olympicin A (**2a**)\
Reagents and conditions: (i) SOCl~2~, 80 °C, 2 h; (ii) AlCl~3~, CS~2~, PhNO~2~, 0.5 h; (iii) TsCl, K~2~CO~3~, acetone, 1 h, 73%; (iv) geranyl bromide, NaH, DMF, 1 h; (v) CH~3~ONa, MeOH, reflux, 8 h, 55% (two-step overall yield); 52% for **2b** (two-step overall yield).](jm-2014-00853v_0008){#sch1}

Next, to further expand the chemical diversity and investigate the influence of 2-substitution on antibacterial activity in the scaffold, an array of racemic olympicin derivatives (**2c**--**e**) and enantiomeric form **2f** were designed and synthesized (Scheme [2](#sch2){ref-type="scheme"}). Compounds **1a′** and **1a** were first protected by reacting with MOMCl in the presence of diisopropylethylamine (DIPEA) to provide **1c** and **1c′** in moderate yields. The O-alkylation reaction was subsequently carried out with appropriate alkyl bromide using sodium hydride as a base, after which the MOM groups were removed with hydrochloric acid to give **2c**--**f** in moderate to high yields (66--93%).

![Synthesis of Olympicin A Analogues\
Reagents and conditions: (i) MOMCl, DIPEA, DCM, 1 h; (ii) R-Br, NaH, DMF; (iii) HCl, MeOH, overnight.](jm-2014-00853v_0009){#sch2}

Synthesis of 2-Substituted 4-Chromanone and Derivatives {#sec2.2}
-------------------------------------------------------

4-Chromanone derivatives bearing an aryl substituent in the 2-position are normally synthesized by reacting an acetophenone with an arylaldehyde under strong basic or acidic conditions.^[@ref49],[@ref50]^ However, because of the side reaction of self-condensation of the aliphatic aldehyde,^[@ref51]^ these conditions are not ideal for the synthesis of 2-alkyl substituted 4-chromanones. Several different synthetic methods to prepare such 4-chromanone derivatives have been reported,^[@ref51]−[@ref53]^ either involving microwave irradiation or requiring very long reaction times. Here, a sealed pressure tube was introduced as a reaction vessel for the preparation of 2-alkyl substituted 4-chromanones. On the basis of the scaffold, several modification strategies (Figure [2](#fig2){ref-type="fig"}) were applied to develop chemical diversity and further evaluate the SAR.

![Modifications based on the 4-chromanone scaffold.](jm-2014-00853v_0003){#fig2}

As shown in Scheme [3](#sch3){ref-type="scheme"}, a series of 2-alkyl-4-chromanone derivatives **3a**--**f** were synthesized by reacting 2,4-dihydroxyacetophenone (**1d**) with an appropriate aliphatic aldehyde in the presence of pyrrolidine in ethanol. This reaction was performed in a sealed pressure tube at 150 °C for 1 h, obtaining yields over 30%. Furthermore, the reaction time was shortened significantly. In contrast, a lower yield (12%) was afforded despite a longer reaction time (72 h) for the synthesis of **3b** under the conditions (ethanol, 60 °C, pyrrolidine). To optimize the reaction conditions, a panel of different amine bases was screened. We noted that under the same conditions, no product was detected using DIPEA and only traces of product were formed when using morpholine as a base monitored by HPLC, respectively. To investigate the potential effects of the 4-carbonyl group as a hydrogen bond acceptor, the 4-chromanones **3a**--**d** were further reduced by NaBH~4~ in methanol to provide 4-chromanol derivatives **4a**--**d** in moderate to good yields (64--81%).^[@ref54]^

![Synthesis of 2-Alkylated 4-Chromanones and Derivatives\
Reagents and conditions: (i) pyrrolidine, EtOH, 150 °C, pressure tube, 1 h; (ii) NaBH~4~, MeOH, rt, 24 h.](jm-2014-00853v_0010){#sch3}

Accordingly, when the bicyclic (−)-myrtenal (**1f**) was used as the substrate under these reaction conditions (Scheme [3](#sch3){ref-type="scheme"}, step i), no product was obtained. Subsequently, a lower temperature (75 °C) was applied (Scheme [4](#sch4){ref-type="scheme"}) to optimize the reaction conditions. The corresponding chalcone intermediate **3g** was obtained in low yield (9.5%). To improve the reaction yield, **1d** was first regioselectively protected by reacting with MOMCl in the presence of DIPEA to provide the MOM-protected acetophenone **1e** in 86% yield. Again, when the reaction was performed at 150 °C, only traces of **3h** were detected by HPLC. In contrast, a much higher yield (48%) was obtained when the reaction temperature was reduced to 75 °C. The MOM-protected **3h** can be further cyclized in ethanol in the presence of sodium acetate to yield 4-chromanone **3i** as a mixture of two diastereomers.^[@ref55]^ Final deprotection of the *O*-MOM group was performed in methanol using concentrated HCl at room temperature to give **3j** in 90% yield.

![Reactions of Acetophenone and (−)-Myrtenal\
Reagents and conditions: (i) DIPEA, MOMCl, 0 °C, 1 h; (ii) pyrrolidine, EtOH, 75 °C, pressure tube, 1 h; (iii) NaOAc, EtOH, reflux, 24 h; (iv) concentrated HCl, MeOH, rt, overnight.](jm-2014-00853v_0011){#sch4}

Next, on the basis of the promising antibacterial activity of **3f**, a focused set of 4-chromanone analogues (Scheme [5](#sch5){ref-type="scheme"}) were subsequently designed and synthesized to investigate the antibacterial effect of the phenol free hydroxy group at different positions. Compound **3f** was resynthesized from the MOM-protected **1e** by using diethylamine (DEA) as a base in an overall 58% yield following *O*-MOM deprotection. Accordingly, **3k**,**l** with the 5- or 6-hydroxy group were also synthesized using appropriate MOM-protected **1g**,**h** in moderate yields (58--75%).

![Synthesis of 4-Chromanone Analogues **3f**, **3k**, and **3l**\
Reagents and conditions: (i) DEA, EtOH, 150 °C, pressure tube, 1 h; (ii) concentrated HCl, MeOH, rt, overnight.](jm-2014-00853v_0012){#sch5}

To further expand the SAR and evaluate the influence of the 5-hydroxy group, an array of 5,7-dihydroxy-4-chromanones were synthesized. Accordingly, 2,4,6-trihydroxyacetophenone (**1j**) was used to prepare 4-chromanone derivatives **5** (Scheme [6](#sch6){ref-type="scheme"}). Unfortunately, no product was obtained under the reaction conditions of pyrrolidine in ethanol at 150 °C in a pressure tube. Therefore, the bis-MOM-protected acetophenone **1k** was next prepared in 79% yield.^[@ref56]^ The corresponding MOM-protected 4-chromanones **5** were obtained by reacting **1k** with an appropriate aldehyde in the presence of DEA in ethanol in a pressure tube at 150 °C in moderate yields (55--70%). Subsequent removal of the MOM groups using concentrated HCl in methanol at room temperature afforded the corresponding 4-chromanones in 75--94% yields. Next, to evaluate the role of the carbonyl group at the 4-position and further explore the chemical diversity of the 4-chromanone scaffold, a panel of 4-oximinochromanes **6a**--**f** were produced by reacting the corresponding **5** with an appropriate hydroxylamine in ethanol in the presence of pyridine in high yields (80--90%). Notably, the reaction time in this series differed from 26 to 72 h, and the electron donating group such as MeO in **6b** greatly facilitated the reaction and reduced the reaction time (26 h).

![Synthesis of 2-Substituted 4-Chromanones and Oxime Derivatives\
Reagents and conditions: (i) DIPEA, MOMCl, 0 °C, 1 h, 79%; (ii) DEA, EtOH, 150 °C, pressure tube, 1 h; (iii) concentrated HCl, MeOH, rt, 24 h; (iv) pyridine, EtOH, rt, 26--72 h.\
Without isolating the MOM-protected intermediate.](jm-2014-00853v_0013){#sch6}

As illustrated in Scheme [7](#sch7){ref-type="scheme"}, to synthesize the bicyclic compound **5n** bearing the myrtenal motif, the reaction time needed to be extended to 4 h under the reaction conditions, and the chalcone **5m** was obtained in overall two-step 34% yield after *O*-MOM deprotection. Subsequent intramolecular conjugate addition of the phenol on the α,β-unsaturated system was performed under microwave irradiation in the presence of catalytic amounts of concentrated HCl to give **5n** in 72% yield as a mixture of two diastereomers.^[@ref49]^ We also noted that the reaction was completed in 0.5 h, which was a great improvement in comparison to the condition of refluxing with sodium acetate in ethanol in Scheme [4](#sch4){ref-type="scheme"}.

![Synthesis of Compounds **5m** and **5n**\
Reagents and conditions: (i) DEA, EtOH, 150 °C, pressure tube, 4 h; (ii) HCl, MeOH, rt, 16 h; (iii) HCl, EtOH, microwave irradiation, 150 °C, 0.5 h.](jm-2014-00853v_0014){#sch7}

Next, 2-spiro-4-chromanones (**7a**--**c**) were synthesized by reacting **1e** with an appropriate cycloketone in a pressure tube at 150 °C for 2--16 h in the presence of pyrrolidine (Scheme [8](#sch8){ref-type="scheme"}). The following *O*-MOM deprotection was performed in one pot with excess concentrated HCl. The spiro compounds **7a**--**c** were obtained in moderate to high yields, with **7c** giving the lowest yield (53%) probably due to the steric hindrance of the seven-membered ring.

![Synthesis of 2-Spiro-4-chromanones **7a**--**c**\
Reagents and conditions: (i) pyrrolidine, EtOH, 150 °C, pressure tube, 2--16 h; (ii) HCl, rt, overnight.](jm-2014-00853v_0015){#sch8}

Synthesis of 2-Substituted Aromatic Chalcone and Flavanone Derivatives {#sec2.3}
----------------------------------------------------------------------

To systematically investigate the SAR of the chalcone and 4-chromanone scaffolds on antibacterial activities, diverse aromatic aldehydes were introduced to synthesize a series of 2-aryl chalcone and flavanone derivatives (Scheme [9](#sch9){ref-type="scheme"}). Accordingly, the Claisen--Schmidt aldol condensations were performed at room temperature with the addition of 60% KOH aqueous solution to the mixture of appropriate MOM-protected acetophenone and aldehyde in methanol.^[@ref55]^ Subsequent removal of the MOM-protecting group with concentrated HCl afforded the chalcone derivatives **8a**--**h**. Chalcone **8f** was synthesized as a comparison under the same conditions to verify the potential effect of 2′-hydroxy group on antibacterial activity. Additionally, in comparison to **8a** with the ortho-substituted allyloxy group, regioisomers **8g** and **8h** (with the allyloxy group at the meta- and para-position, respectively) were next synthesized to investigate the influence of the substitution at the R~2~ position in the scaffold. Subsequent intramolecular conjugate additions of the phenol on the α,β-unsaturated system of **8a**--**e** were carried out under microwave irradiation in the presence of catalytic amounts of concentrated HCl to yield corresponding flavanones **8i**--**m** in 50--75% yields.

![Synthesis of 2-Substituted Aromatic Chalcones and Flavanones\
Reagents and conditions: (i) 60% KOH aq, MeOH, rt, 60 h; (ii) concentrated HCl, rt, overnight; (iii) microwave, HCl, EtOH, 150 °C, 1.5 h.\
Without 2′-OH function for **8f**.](jm-2014-00853v_0016){#sch9}

All the synthesized compounds were characterized by ^1^H and ^13^C NMR spectroscopy and high-resolution mass spectrometry (HRMS), and purity was analyzed by reverse phase HPLC. The structures of **3g** and **8a** were confirmed by X-ray crystallography, and their ORTEP drawings are shown in Figure S1 ([Supporting Information](#notes-2){ref-type="notes"}).

All the synthesized compounds were evaluated against *Mycobacterium tuberculosis* (H37Rv) and a wide set of clinically relevant Gram-positive and -negative bacterial pathogens including *Enterococcus faecalis* (ATCC 33186), *Staphylococcus aureus* (ATCC 29213 and NRS 70), *Escherichia coli* (K12 and Δ*tolC*), *Klebsiella pneumoniae* (ATCC 33495), and *Pseudomonas aeruginosa* (PAO1). Their antitubercular and antibacterial activities are summarized in Tables [1](#tbl1){ref-type="other"}--[3](#tbl3){ref-type="other"}.

Olympicin A Series {#sec2.3.1}
------------------

In the olympicin A series, olympicin A (**2a**) and analogues (**2b**--**f**) showed weak antitubercular activity with MICs of 100--200 μg/mL (Table [1](#tbl1){ref-type="other"}). The observed weak antituberculosis activity may be attributed to the general polar nature of this chemical series and decreased membrane penetration. In contrast, the olympicin derivatives with geranyloxy (**2a** and **2b**), *n*-hexyloxy (**2d**), and *n*-octyloxy (**2e**) groups showed good to potent anti-Gram-positive activity against *E. faecalis* and *S. aureus* strains (MIC = 0.78--3.13 μg/mL). However, the less lipophilic olympicin derivatives **2c** and **2f** with a shorter allyloxy chain exhibited about 8- to 16-fold decrease of antibacterial activity (MIC = 6.25--12.5 μg/mL). In terms of stereochemistry effect, the racemic olympicin A (**2b**) and allyloxy derivative (**2c**) showed largely the same antituberculosis and anti-Gram-positive activity compared to their corresponding chiral *S*-isomers **2a** and **2f**, respectively. Notably, the anti *S. aureus* activity (1.56 μg/mL) of our synthetic sample (**2a**) of olympicin A is consistent with the previously reported anti *S. aureus* activity (0.5--1 μg/mL) of natural olympicin A.^[@ref44]^ In addition, none of these olympicin analogues were active against Gram-negative microorganisms except for the reengineered *E. coli* strain (Δ*tolC*) with deficient efflux activity.

###### Antibacterial Activities (MIC, μg/mL) of Olympicin A and Derivatives[a](#t1fn1){ref-type="table-fn"}

![](jm-2014-00853v_0017){#fx1}

No test compounds were active (\>200 μg/mL) against other Gram-negative bacteria including *K. pneumonia* (ATCC 33495) and *P. aeruginosa* (PAO1).

Positive controls isoniazid and rifampin inhibited *M. tuberculosis* at 0.03 and 0.05 μg/mL, respectively.

nd = not determined.

4-Chromanone and Chalcone Series. Antituberculosis Activity {#sec2.3.2.1}
-----------------------------------------------------------

In the 4-chromanone and chalcone chemical series (Tables [2](#tbl2){ref-type="other"} and [3](#tbl3){ref-type="other"}), the majority of compounds exhibited weak antituberculosis activity. The 2-propyl-4-chromanol **4a** showed the most potent activity in the entire series with a MIC of 12.5 μg/mL. The reduced 4-chromanol variants **4a** and **4c** (4-OH, 12.5 and 25 μg/mL, respectively) showed more potent antituberculosis activity than their corresponding 4-chromanones **3a** (200 μg/mL) and **3c** (50 μg/mL). In addition, the 4-oximinochromane **6a** (=NOH, 100 μg/mL) displayed greater potency than **6b** (=NOMe, 200 μg/mL) and **6c** (=NOBn, \>200 μg/mL). Taken together, these results indicate that the small, polar, and hydrophilic groups (e.g., −OH and =NOH) are more favorable at the 4-position of the flavonoid scaffold for antituberculosis activity, suggesting these polar groups may function as hydrogen bond donors when interacting with potential biological cellular target.

Different lengths of the 2-alkyl side chains in the scaffold displayed an important relationship with antituberculosis activity as well. Compared to **3a** (three-carbon, 200 μg/mL), **3b** (six-carbon, 50 μg/mL), and **3c** (seven-carbon, 50 μg/mL), compound **3d** with a nine-carbon linear chain was inactive, suggesting the nine-carbon alkyl group is too long and bulky. To investigate the impact of the substituent at the 5-position in the scaffold, a hydrogen bond donor and/or acceptor (hydroxy group) was introduced. These data showed that the compounds bearing 5,7-dihydroxy functionalities (**5b**, **5d**, and **5f**) exhibited similar MIC values to the sole 7-hydroxychromanones **3a**--**c**. However, **5h** (5,7-di-OH, nine-carbon chain, 100 μg/mL) was more potent than the corresponding **3d** (7-OH, nine-carbon chain, \>200 μg/mL). In addition, the position of the sole hydroxy group in the scaffold also played a notable role in their antituberculosis activity by comparing **3f** (7-OH, 100 μg/mL) to **3k** (6-OH, 200 μg/mL) and **3l** (5-OH, \>200 μg/mL), with **3f** bearing the 7-hydroxy function being the most potent.

In general, 2-aryl substituted compounds together with 2-spiro derivatives possessing a cyclic ring system were less active against *M. tuberculosis* than 2-alkylated derivatives in the entire series. Moreover, the MOM protected derivatives exhibited comparable or more potent antitubercular activity than their corresponding free phenol parent molecules. The SAR analysis above demonstrates that the 2-alkyl hydrophobic substituents as well as the small and polar functionalities at the 4-position (e.g., hydrogen bond donor groups OH and =NOH) play important roles in antituberculosis activities in the 4-chromanone scaffold.

###### Antibacterial Activities (MIC, μg/mL) of 4-Chromanone Derivatives[a](#t2fn1){ref-type="table-fn"}

![](jm-2014-00853v_0018){#fx2}

![](jm-2014-00853v_0019){#fx3}

![](jm-2014-00853v_0020){#GRAPHIC-d3295e1270-autogenerated}

No test compounds were active (\>200 μg/mL) against other Gram-negative bacteria including *K. pneumonia* (ATCC 33495) and *P. aeruginosa* (PAO1). The MIC values of control antibiotics used in this study are shown in Table [1](#tbl1){ref-type="other"}.

General Antibacterial Spectra {#sec2.4}
-----------------------------

In addition to antituberculosis evaluation, antimicrobial assessment against representative clinical pathogens revealed that the majority of compounds from these series exhibited notable anti-Gram-positive bacteria activities including against *E. faecalis* and *S. aureus* (MSSA and MRSA) and poor activity against Gram-negative bacteria including *E. coli*, *K. pneumoniae*, and *P. aeruginosa*.

Compared with the 4-chromanone flavonoid series, the chalcone series generally exhibited more potent anti-Gram-positive activity than their corresponding cyclized derivatives. The 2′,4′-di-OH chalcone compound **8a** having an appended 2-allyloxy group exhibited the best activity (MIC of 0.39--6.25 μg/mL) against MSSA and MRSA, and the *o*-hydroxy group appeared to have a beneficial effect on anti-Gram-positive bacterial activity by comparing **8a** (2′,4′-di-OH, 2-allyloxy, 0.39--12.5 μg/mL) to **8f** (4′-OH, 2-allyloxy, 6.25--100 μg/mL) (Table [3](#tbl3){ref-type="other"}). Notably, this observation regarding the importance of the *o*-hydroxy group in the chalcone scaffold is also in agreement with that found in the 4-chromanone flavonoid series, whereas the corresponding hydroxy group at the 5-position of the 4-chromanone scaffold enhanced the antibacterial activity. However, the 2′,4′,6′-tri-OH chalcone compounds possessing an additional 6′-hydroxy group **5m** (25 to \>200 μg/mL) and **8e** (25 to \>200 μg/mL) showed significantly decreased activities against Gram-positive microorganisms compared to the 2′,4′-di-OH chalcones **3g** (1.56--3.13 μg/mL) and **8a** (0.39--12.5 μg/mL), respectively. The notable decreased activity for trihydroxy compounds is likely due to increased hydrophilicity and polarity properties and thus decreased bacterial membrane penetration. Taken together, these data suggest that two free phenol hydroxy groups on the 4-chromanone and chalcone scaffolds are optimal for Gram-positive antibacterial activity.

Furthermore, in the chalcone series (Table [3](#tbl3){ref-type="other"}), the lipophilic *O*-alkyl substituent at the 2-position of aromatic chalcones also had a great impact on antibacterial activities, since the chalcones bearing diverse side chains such as the allyloxy (**8a**), *n*-hexyloxy (**8b**), and *n*-octyloxy (**8c**) exhibited notable differences in their activities; compound **8b** bearing the *n*-hexyloxy group showed optimal antibacterial activity against *E. faecalis*, MSSA, and MRSA (1.56, 3.13, and 0.78 μg/mL, respectively). Compound **8a** bearing the 2-allyloxy function demonstrated 2-fold more potent activity against MRSA and an 8-fold reduction in activity against *E. faecalis* than **8b**.

In the flavonoid series, the length of 2-alkyl substitutions in the 4-chromanone scaffold plays an important role in determining antibacterial activities. The 5,7-dihydroxy-4-chromanones with long aliphatic alkyl chains **5d**, **5f**, **5h**, and **5j** (six to nine-carbon chain, 3.13--6.25 μg/mL) showed better activity against MRSA than the shorter chain derivative **5b** (three-carbon chain, 100 μg/mL), and notably, the 2-(2,6-dimethyl-5-heptenyl) substituted **5j** with a branched and unsaturated alkyl chain displayed the best potency among these five 2-alkylated derivatives against three Gram-positive bacteria tested (*E. faecalis*, MSSA, and MRSA; 6.25, 3.13, and 3.13 μg/mL, respectively). These results suggest that the branched unsaturated substitution in **5j** may play an important role in enhancing interactions and binding affinity with cellular biological target because of its favorable lipophilicity and high conformational flexibility, as previously noted for the prenylated derivatives.^[@ref57],[@ref58]^ We also observed that the introduction of an additional 5-OH group to the 7-hydroxy-4-chromanones **5b** (100 μg/mL), **5d** (6.25 μg/mL), **5f** (3.13 μg/mL), **5h** (3.13 μg/mL), and **5n** (6.25 μg/mL) significantly improved antibacterial activity against MRSA, compared to their corresponding 7-OH-4-chromanones **3a**--**d** (\>200 μg/mL) and **3j** (200 μg/mL) except that **5j** maintained anti-MRSA activity (3.13 μg/mL) compared to **3f**. These data demonstrate the importance of the 5-OH group in the 7-OH-4-chromanone scaffold for antibacterial activity.

In addition, the reduced variants 4-chromanols **4a**--**d** (in particular 2-*n*-heptyl-7-OH-4-chromanol **4c**, 12.5--25 μg/mL; and 2-*n*-nonyl-7-OH-4-chromanol **4d**, 25--50 μg/mL) also displayed improved antibacterial activities compared to their corresponding 4-chromanones **3a**--**d**, which were not active against Gram-positive bacteria tested. In contrast, the 4-oximinochromanes (**6a** and **6d**-**f**: =NOH at the 4-position) showed more potent activity against *E. faecalis* and MSSA and comparable activity against MRSA than their corresponding 4-chromanones (**5h**, **5b**, **5d**, and **5f**), suggesting the free oxime =NOH functionality is preferred compared to the carbonyl group. Furthermore, by comparison of **6a** with the free 4-oxime functionality (=NOH, 12.5 μg/mL), compounds **6b** (=NOMe, 25--100 μg/mL) and **6c** (=NOBn, \>200 μg/mL) showed decreased antibacterial activity against *S. aureus*. This observation is also consistent with the trend toward the antituberculosis activity found in this series, indicating that the small, polar, and hydrogen bond donor functionalities (e.g., −OH and =NOH groups) at the 4-position may be more favorable for antibacterial properties, together with the results based upon 4-chromanols (**4a**--**d**).

To further evaluate the importance of the 5-, 6-, and 7-OH functionality, a set of 4-chromanone derivatives **3f** (7-OH), **3k** (6-OH), and **3l** (5-OH) were subsequently synthesized. Biological evaluation revealed that the 6- or 7-hydroxy group also proved to be a determining factor for antibacterial activities, since **3f** (7-OH, 3.13--12.5 μg/mL) and **3k** (6-OH, 6.25--12.5 μg/mL) demonstrated almost equally potent antibacterial activities against Gram-positive bacteria tested. However, their regioisomer **3l** with the 5-OH substitution was not active. The lack of antibacterial activity of **3l** may be due to the presence of intramolecular hydrogen bonding between the carbonyl group at the 4-position and the hydroxy group at the 5-position. It should be noted that all the MOM protected derivatives (**3h**, **3i**, **5a**, **5c**, **5e**, **5g**, and **5i**) completely lost anti-Gram-positive bacterial activities against *E. faecalis* and *S. aureus*, demonstrating the importance of the free phenol hydroxy functionality and its weakly acidic nature in the scaffold. This observation is consistent with our previous report.^[@ref43]^ Additionally, among the chemical series bearing a cyclic/bicyclic ring system at the 2-position (**5k**, 2-cyclopentyl; **5l**, 2-cyclohexyl; **5n**, 2-myrtenyl; and the 2-spiro compounds **7a**--**c**), compound **5n** bearing the myrtenyl motif showed relatively good antibacterial activity (6.25--12.5 μg/mL) against Gram-positive bacteria tested. In contrast, the 7-OH and 2-myrtenyl substituted flavonoid **3j** was largely inactive. Interestingly, its corresponding ring-opened chalcone derivative **3g** demonstrated very good anti-Gram-positive activity (1.56--3.13 μg/mL).

###### Antibacterial Activities (MIC, μg/mL) of Chalcones and Derivatives[a](#t3fn1){ref-type="table-fn"}

![](jm-2014-00853v_0021){#fx4}

![](jm-2014-00853v_0022){#fx5}

No test compounds were active (\>200 μg/mL) against other Gram-negative bacteria including *K. pneumonia* (ATCC 33495) and *P. aeruginosa* (PAO1). The MIC values of control antibiotics used in this study are shown in Table [1](#tbl1){ref-type="other"}.

A detailed SAR of the 4-chromanone and chalcone series is summarized in Figure [3](#fig3){ref-type="fig"}.

![General SAR of 4-chromanone and chalcone derivatives.](jm-2014-00853v_0004){#fig3}

Solubility and Cytotoxicity Determination {#sec2.4.1}
-----------------------------------------

Cytotoxicity against mammalian (Vero epithelial) cells and solubility in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) were evaluated for a selected panel of 4-chromanone and chalcone lead compounds, and the results are shown in Table [4](#tbl4){ref-type="other"}. Overall, all the tested compounds had good solubility (≥100 μg/mL) in the DMEM/FBS medium used in the cytotoxicity assay except for the 4-oxime derivative **6a** (37.5 ± 17.7 μg/mL). The selectivity indices (SI) for the compounds were calculated as the ratio of the IC~50~ value of cytotoxicity against Vero monkey kidney cell line and the MIC value against tested MRSA. Notably, 4-chromanone derivatives **5f** (SI = 10.5) and **8j** (SI = 15.7) and the chalcone derivative **8a** (SI = 54.4) possessed a more favorable selectivity index (SI \> 10). On the basis of these promising antibacterial lead structures, advanced medicinal chemistry will be applied to produce compounds with improved potency and decreased cytotoxicity.

###### Cytotoxicity and Solubility Profiles of Selected Lead Compounds[a](#t4fn1){ref-type="table-fn"}

  compd                                  molecular weight (g/mol)             lipophilicity (cLogP)[b](#t4fn2){ref-type="table-fn"}   solubility (μg/mL)   cytotoxicity IC~50~ (μg/mL)[c](#t4fn3){ref-type="table-fn"}   MIC against MRSA (μg/mL)   selectivity index (SI)[d](#t4fn4){ref-type="table-fn"}
  -------------------------------------- ------------------------------------ ------------------------------------------------------- -------------------- ------------------------------------------------------------- -------------------------- --------------------------------------------------------
  **3f**                                 288.2                                3.77                                                    \>200                28.8 ± 1.8                                                    3.13                       9.2
  **3g**                                 284.1                                3.19                                                    \>200                6.9 ± 0.3                                                     1.56                       4.4
  **5f**                                 278.2                                3.20                                                    150.0                33.0 ± 2.1                                                    3.13                       10.5
  **5h**                                 306.2                                4.03                                                    \>200                8.6 ± 2.7                                                     3.13                       2.8
  **5j**                                 304.2                                3.38                                                    \>200                27.0 ± 2.8                                                    3.13                       8.6
  **6a**                                 321.2                                4.42                                                    37.5 ± 17.7          10.1 ± 1.9                                                    12.5                       0.8
  **6f**                                 293.2                                3.59                                                    \>200                9.6 ± 0.1                                                     3.13                       3.1
  **8a**                                 296.1                                3.37                                                    \>200                21.2 ± 5.4                                                    0.39                       54.4
  **8b**                                 340.2                                4.76                                                    \>200                7.2 ± 0.4                                                     0.78                       9.2
  **8d**                                 323.2                                3.82                                                    100.0                16.7 ± 0.1                                                    3.13                       5.3
  **8j**                                 340.2                                4.36                                                    \>200                24.5 ± 2.1                                                    1.56                       15.7
  **8k**                                 368.2                                5.19                                                    \>200                17.0 ± 0.0                                                    3.13                       5.4
  thioridazine                           nd[e](#t4fn5){ref-type="table-fn"}   nd                                                      nd                   5.3 ± 1.3                                                     nd                         nd
  verapamil                              nd                                   nd                                                      nd                   57.3 ± 3.2                                                    nd                         nd
  DMSO[f](#t4fn6){ref-type="table-fn"}   nd                                   nd                                                      nd                   177.5 ± 10.6                                                  nd                         nd

DMEM/FBS: Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS).

The cLogP values of compounds were calculated using ChemBioOffice Ultra, version 12.0, from CambridgeSoft Corporation.

Cytotoxicity IC~50~, concentration that reduces viability of Vero kidney cells by 50%.

Selectivity index = (cytotoxic IC~50~)/(MIC against MRSA).

nd = not determined.

Carrier effect.

Time Kill Experiments and Mutation Selection {#sec2.4.2}
--------------------------------------------

The bactericidal activities of compounds **3g**, **5j**, **8a**, and **8d** were examined against *S. aureus* Newman (Figure [4](#fig4){ref-type="fig"}). The most effective compound was the chalcone derivative **3g**, which killed more than 6 log of cells in just 2 h at 4× its MIC, but at its MIC (1.56 μg/mL against *S. aureus* Newman) up to 24 h was required to achieve a 3 log reduction in cells. Compound **3g** thus exhibited concentration-dependent killing. Compound **8a** (MIC = 6.25 μg/mL) was also rapidly bactericidal at 4× its MIC and achieved a 6 log reduction in 6 h. Interestingly, compound **8d** (6.25 μg/mL) was entirely bacteriostatic and failed to kill more than 3 log of culture at 4 × its MIC, even up to 24 h of exposure. At concentrations between 1× and 4× their MICs, spontaneous mutants of *S. aureus* Newman could not be selected with **8a**, **3g**, and **5j**, but mutants arose to **8d** at a frequency of 10^--10^. The controls mupirocin and vancomycin were either bacteriostatic or slowly bactericidal over a 24 h period, and mutants could only be selected with mupirocin at frequencies of 10^--7^--10^--9^.

![Time kill studies against *S. aureus* Newman exposed to 4× MIC of compounds. Each point represents the average of two biological replicates.](jm-2014-00853v_0005){#fig4}

Effects on Macromolecular Synthesis and Membrane Potential {#sec2.4.3}
----------------------------------------------------------

Several key biosynthetic processes were simultaneously inhibited in *S. aureus* Newman exposed to the compounds **2a**, **5j**, **8a**, **3g**, and **8d** (Figure [5](#fig5){ref-type="fig"}). These effects are consistent with the bacterial membrane being the primary target site of action, resulting in multiple nonspecific cellular effects. Surprisingly, the bacteriostatic compound **8d** displayed the same time-dependent effects on macromolecular synthesis as the bactericidal compounds. To determine if the compounds dissipated the membrane potential of *S. aureus*, the fluorescent probe DiOC2(3) was used. Compounds **2a**, **5j**, **3g**, and **8d** all dissipated the membrane potential of *S. aureus* Newman in a concentration-dependent manner. Maximum dissipation occurred at 4× their MICs and was similar to the control CCCP (carbonyl cyanide *m*-chlorophenylhydrazone) (Figure [6](#fig6){ref-type="fig"}); as expected, vancomycin (at 4× MIC) failed to affect the membrane potential in *S. aureus*.

![Effects of **2a**, **5j**, **3g**, **8a**, and **8d** and indicated positive controls at 4× their MICs on macromolecular synthesis in *S. aureus* Newman. The standard error of the mean (SEM) is shown for three biological replicates. ERY = erythromycin (MIC = 0.78 μg/mL); RMP = rifampicin (0.12 μg/mL); CIP = ciprofloxacin (0.25 μg/mL).](jm-2014-00853v_0006){#fig5}

![Dissipation of the staphylococcal membrane potential by **2a**, **5j**, **3g**, and **8d**. A representative of three biological replicates is shown. Vancomycin (MIC = 0.8 μg/mL) and CCCP (MIC = 6.25 μg/mL) were used as negative and positive controls.](jm-2014-00853v_0007){#fig6}

Inhibition of Bacterial Topoisomerase IV and DNA Gyrase {#sec2.4.4}
-------------------------------------------------------

Clinically, DNA gyrase and topo IV are validated and attractive antibacterial targets for fluoroquinolone and novobiocin antibiotics. However, because of the emergence of target-based bacterial resistance with fluoroquinolone class and safety concerns of novobiocin, novel DNA gyrase and topoisomerase inhibitors are urgently needed for the treatment of pathogenic and resistant bacterial infections.^[@ref59]^ Thus, development of new chemotype bacterial topo inhibitors has attracted great interest in the scientific community, and recent examples include bisbenzimidazoles,^[@ref60]^ anziaic acid, and its analogues^[@ref61],[@ref62]^ as bacterial topo IA inhibitors, and pyridylureas^[@ref63]^ and pyrrolamides^[@ref59]^ as topo II inhibitors. Previously, flavonoids have been identified as bacterial topoisomerase inhibitors,^[@ref64]−[@ref66]^ and we next tested to see if these promising antibacterial compounds from olympicin A, 4-chromanone, and chalcone series inhibited *E. coli* topo I, topo IV, and DNA gyrase. The results are shown in Table [5](#tbl5){ref-type="other"} and Figure S2 ([Supporting Information](#notes-2){ref-type="notes"}). The *E. coli* topo I assay (relaxation of negatively supercoiled plasmid DNA) was performed at both 0.5 and 5 mM magnesium chloride concentrations, and no significant inhibition was observed against topo I at 0.5 mM compound concentration. The assay against *E. coli* gyrase (supercoiling of relaxed plasmid DNA) and *E. coli* topo IV (decatenation of catenated kinetoplast DNA) was subsequently performed. Again for DNA gyrase, inhibition was not observed or was weak with **8a**, **3g**, and **2a** (MIC values of 0.39--6.25 μg/mL against *S. aureus*) exhibiting IC~50~ values of \>0.25 mM. However, the *E. coli* topo IV showed more significant sensitivity toward **2a** and **2e** (MIC values of 0.78--1.56 μg/mL against *E. faecalis* and *S. aureus*) with IC~50~ values of 30--60 μM (Table [5](#tbl5){ref-type="other"} and Figure S2, [Supporting Information](#notes-2){ref-type="notes"}). These results showed that the olympicin A (**2a**) and its analogue **2e** may serve as a promising and novel scaffold for topo IV inhibitors. Interestingly, olympicin A was also recently reported as a moderate ATP-dependent *Mycobacterium tuberculosis* MurE ligase inhibitor with an IC~50~ value of 75 μM.^[@ref45]^ Studies to determine if the olympicin A analogues **2c**--**f** inhibit the MurE pathway in *M. tuberculosis* remain to be performed. Finally, the antibacterial mechanism of the 4-chromanone flavanone compounds **8k** and **8j** (MIC values of 1.56--12.5 μg/mL against *S. aureus*) may not be likely to involve topoisomerase inhibition, as they were inactive in these topo enzyme inhibition assays (Table [5](#tbl5){ref-type="other"}). Collectively, no correlations between whole-cell-based activity and topoisomerase inhibition were observed for selected compounds, suggesting that the membrane is likely the primary biological target responsible for antibacterial activity and topo IV is a secondary or alternative target. Further mechanistic studies are warranted to define the exact mechanism of antibacterial action of these chemically modified flavonoid and polyphenol compounds.

###### *E. coli* Topoisomerases and DNA Gyrase Inhibition of Selected Analogues

  compd              topo I IC~50~ (μM)                       DNA gyrase IC~50~ (μM)                                                     topo IV IC~50~ (μM)
  ------------------ ---------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------
  **2a**             \>500                                    500--1000                                                                  30--60
  **2e**             \>500                                    \>1000                                                                     30--60
  **3g**             \>500                                    250--500                                                                   60--120
  **5f**             \>500                                    \>1000                                                                     120--250
  **8a**             \>500                                    500--1000                                                                  250--500
  **8b**             \>500                                    \>1000                                                                     60--120
  **8d**             \>500                                    \>1000                                                                     500--1000
  **8j**             \>500                                    \>1000                                                                     \>1000
  **8k**             \>500                                    \>1000                                                                     \>1000
  known inhibitors   14--19[a](#t5fn2){ref-type="table-fn"}   0.2,[b](#t5fn3){ref-type="table-fn"} 100[c](#t5fn4){ref-type="table-fn"}   2.1,[b](#t5fn3){ref-type="table-fn"} 806[c](#t5fn4){ref-type="table-fn"}

IC~50~ of known inhibitor for assay: anziaic acid^[@ref61]^ for Topo I.

IC~50~ of known inhibitor for assay: ciprofloxacin^[@ref67]^ for DNA gyrase and topo IV.

IC~50~ of known inhibitor for assay: nalidixic acid^[@ref68]^ for DNA gyrase and topo IV.

Conclusions {#sec3}
===========

In summary, 58 olympicin A, 4-chromanone, and chalcone derivatives containing various functionalities were synthesized and evaluated against *Mycobacterium tuberculosis* and a panel of clinically relevant Gram-positive and -negative bacterial pathogens. Bacterial evaluation showed that this class of compounds generally exhibited good activities against Gram-positive bacteria tested. Systematic SAR study revealed that the phenol hydroxy groups at the 5- and 7-position of the 4-chromanone scaffold were essential for antibacterial activities. Additionally, the hydrogen bond donor/acceptor functionality at the 4-position together with the lipophilic 2-alkyl moiety in the scaffold also played important roles in antibacterial activities. The flavanone derivatives bearing the lipophilic substituent on the 2-phenyl ring showed good antibacterial properties as well. In the chalcone chemical series, both hydroxy groups at 2′- and 4′-position, as well as the bicyclic myrtenyl motif and the 2-alkyloxy substitution on the aromatic ring, favored anti-Gram-positive bacterial activities. The selected compounds generally possessed favorable solubility, and **5f**, **8a**, and **8j** had more desirable selectivity indices ranging from 10.5 to 54.4. In addition, compounds **2a**, **5j**, **3g**, and **8d** were found to disrupt bacterial membrane potential and have secondary inhibitory effect on macromolecular biosynthesis of DNA, RNA, and protein. Further evaluation of selected compounds against bacterial topoisomerases and DNA gyrase revealed that **2a** and **2e** inhibited topoisomerase IV (IC~50~ = 30--60 μM). Taken together, the antibacterial agents identified from this study provide chemically modified flavonoid phytochemicals as promising antibacterial leads for further medicinal chemistry optimization in an effort to identify advanced experimental candidates with antimicrobial therapeutic potential.

Experimental Section {#sec4}
====================

Chemical Synthesis. General Procedures {#sec4.1.1}
--------------------------------------

Solvents and reagents were supplied from Aldrich, Acros, or Fisher and used without further purification. NMR spectra were recorded on a Bruker AM-400 (400 MHz) spectrometer. High-resolution mass spectra were obtained on an Agilent 6530 Accurate Mass Q-TOF LC/MS instrument. Reactions in pressure tube were carried out using a Q-Tube reactor from Q Labtech. Microwave reactions were conducted using a Biotage Initiator reactor. All reactions were monitored by either TLC or HPLC. Compounds were purified by flash chromatography on silica gel on a Biotage Isolera One system. The purity of compounds was determined by analytical HPLC (Shimadzu LC-20A series) using a Gemini, 3 μm, C18, 110 Å column (50 mm × 4.6 mm, Phenomenex) and flow rate of 1 mL/min. Gradient conditions were the following: solvent A (0.1% trifluoroacetic acid in water) and solvent B (acetonitrile), 0--2.0 min 100% A, 2.0--7.0 min 0--100% B (linear gradient), 7.0--8.0 min 100% B, UV detection at 254 and 220 nm. All the tested compounds were obtained with ≥95% purity by HPLC. NMR standards used are as follows. ^1^H NMR: CDCl~3~, 7.26 ppm; CD~3~OD, 3.31 ppm; DMSO-*d*~6~, 2.50 ppm. ^13^C NMR: CDCl~3~, 77.16 ppm; CD~3~OD, 49.00 ppm; DMSO-*d*~6~, 39.52 ppm. MOM-protected acetophenones were synthesized as described in the literature.^[@ref56],[@ref69],[@ref70]^

(*S*)-2-(2-Methylbutanoyl)benzene-1,3,5-triyl Tris(4-methylbenzenesulfonate) (**1b**) {#sec4.1.2}
-------------------------------------------------------------------------------------

To a solution of **1a** (150 mg, 0.715 mmol) in acetone (11 mL) were added *p*-toluenesulfonic chloride (408 mg, 2.14 mmol) and K~2~CO~3~ (845 mg, 6.15 mmol) successively. The resulting mixture was stirred under reflux for 1 h, and then acetone was removed under reduced pressure. The residue was diluted with water and DCM, and the organic layer was washed with 1 M HCl aq, water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc (first 85/15, then 75/25) to give the product (350 mg, 0.52 mmol, 73%) as clear oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.69 (d, *J* = 8.3 Hz, 2H), 7.62 (d, *J* = 8.4 Hz, 4H), 7.36 (d, *J* = 8.2 Hz, 2H), 7.30 (d, *J* = 8.3 Hz, 4H), 7.0 (s, 2H), 2.64--2.59 (m, 1H), 2.44 (s, 9H), 1.56--1.50 (m, 1H), 1.24--1.14 (m, 1H), 0.90 (d, *J* = 7.0 Hz, 3H), 0.76 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 201.2, 149.8, 146.8, 146.5, 146.4, 131.7, 131.3, 130.2, 130.0, 128.5, 127.1, 114.3, 48.6, 24.5, 21.80, 21.79, 14.2, 11.2. HRMS calculated for C~32~H~32~O~10~S~3~ (M + H)^+^ 673.1230, found (M + H)^+^ 673.1229. HPLC purity: 98.6% (254 nm), *t*~R~ = 8.17 min; 99.5% (220 nm), *t*~R~ = 8.17 min.

1-(2-Hydroxy-4,6-bis(methoxymethoxy)phenyl)-2-methylbutan-1-one (**1c**) {#sec4.1.3}
------------------------------------------------------------------------

To a suspension of **1a′** (1.12 g, 5.33 mmol) in DCM (11 mL) at 0 °C was added DIPEA (2.78 mL, 15.9 mmol) carefully. After stirring for 10 min, MOMCl (1.21 mL, 15.9 mmol) was added to the solution dropwise. The resulting mixture was stirred for 1 h. Afterward, the solution was poured into sat. NH~4~Cl aq, and then water and DCM were added into the mixture. The organic layer was washed with water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc (90/10) to give the product (1.02 g, 3.42 mmol, 64%) as pale yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 13.74 (s, 1H), 6.27 (s, 2H), 5.24 (s, 2H), 5.16 (br s, 2H), 3.65--3.60 (m, 1H), 3.51 (s, 3H), 3.46 (s, 3H), 1.87--1.80 (m, 1H), 1.43--1.36 (m, 1H), 1.16 (d, *J* = 6.8 Hz, 3H), 0.91 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 210.3, 167.2, 163.2, 160.1, 106.7, 97.6, 94.9, 94.4, 94.1, 56.9, 56.6, 46.6, 27.1, 16.7, 12.2. HRMS calculated for C~15~H~22~O~6~ (M + H)^+^ 299.1489, found (M + H)^+^ 299.1483. HPLC purity: 99.8% (254 nm), *t*~R~ = 7.42 min; 99.8% (220 nm), *t*~R~ = 7.42 min.

(*S*)-1-(2-Hydroxy-4,6-bis(methoxymethoxy)phenyl)-2-methylbutan-1-one (**1c′**) {#sec4.1.4}
-------------------------------------------------------------------------------

Synthesis and purification were performed as described in compound **1c**. Product: 1.03 g, 3.46 mmol, 65%. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 13.74 (s, 1H), 6.27 (s, 2H), 5.24 (s, 2H), 5.16 (br s, 2H), 3.65--3.60 (m, 1H), 3.52 (s, 3H), 3.46 (s, 3H), 1.87--1.80 (m, 1H), 1.43--1.36 (m, 1H), 1.16 (d, *J* = 6.8 Hz, 3H), 0.91 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 210.3, 167.2, 163.2, 160.1, 106.7, 97.6, 94.9, 94.4, 94.1, 56.8, 56.6, 46.6, 27.1, 16.7, 12.1. HRMS calculated for C~15~H~22~O~6~ (M + H)^+^ 299.1489, found (M + H)^+^ 299.1475. HPLC purity: 99.9% (254 nm), *t*~R~ = 7.38 min; 100% (220 nm), *t*~R~ = 7.38 min.

General Procedure for the Synthesis of **2a**,**b** {#sec4.2}
---------------------------------------------------

To a solution of **1b** (410 mg, 0.61 mmol) in DMF (4 mL) at 0 °C was added NaH (49 mg, 1.21 mmol) carefully. After stirring for 30 min, geranyl bromide (198 mg, 0.91 mmol) in DMF (1 mL) was added dropwise. The resulting mixture was stirred at room temperature for 1 h. Afterward, the reaction was quenched with water and extracted with EtOAc twice. The organic layer was washed with water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure, and the residue was dissolved in MeOH (10 mL), followed by the careful addition of sodium methoxide (659 mg, 12.2 mmol). The resulting mixture was stirred under reflux for 8 h, and then MeOH was removed. The residue was diluted with 1 M HCl aq and extracted with EtOAc twice. The organic layer was washed with water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc to give the product.

### (*S*,*E*)-1-(2-((3,7-Dimethylocta-2,6-dien-1-yl)oxy)-4,6-dihydroxyphenyl)-2-methylbutan-1-one (Olympicin A, **2a**) {#sec4.2.1}

Purified with hexane/EtOAc (90/10) to give the product (116 mg, 0.34 mmol, 55%, two-step overall yield) as pale yellow oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 5.98 (d, *J* = 2.2 Hz, 1H), 5.91 (d, *J* = 2.2 Hz, 1H), 5.54 (br, 1H), 5.52--5.49 (m, 1H), 5.11--5.09 (m, 1H), 4.56 (d, *J* = 6.6 Hz, 2H), 3.67--3.63 (m, 1H), 2.14--2.08 (m, 4H), 1.81--1.78 (m, 1H), 1.74 (s, 3H), 1.68 (s, 3H), 1.61 (s, 3H), 1.40--1.33 (m, 1H), 1.12 (d, *J* = 6.7 Hz, 3H), 0.89 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 210.8, 167.3, 163.1, 162.8, 142.6, 132.1, 123.7, 118.3, 105.8, 96.6, 92.1, 65.8, 46.1, 39.6, 27.0, 26.4, 25.8, 17.8, 16.73, 16.67, 12.0. HRMS calculated for C~21~H~30~O~4~ (M + H)^+^ 347.2217, found (M + H)^+^ 347.2210. HPLC purity: 99.7% (254 nm), *t*~R~ = 8.18 min; 99.6% (220 nm), *t*~R~ = 8.18 min.

### (*E*)-1-(2-((3,7-Dimethylocta-2,6-dien-1-yl)oxy)-4,6-dihydroxyphenyl)-2-methylbutan-1-one (**2b**) {#sec4.2.2}

Purified with hexane/EtOAc (90/10) to give the product (110 mg, 0.32 mmol, 52% over two steps) as pale yellow oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 5.98 (d, *J* = 2.2 Hz, 1H), 5.91 (d, *J* = 2.2 Hz, 1H), 5.54 (br, 1H), 5.52--5.49 (m, 1H), 5.11--5.09 (m, 1H), 4.56 (d, *J* = 6.6 Hz, 2H), 3.67--3.63 (m, 1H), 2.14--2.08 (m, 4H), 1.81--1.78 (m, 1H), 1.74 (s, 3H), 1.68 (s, 3H), 1.61 (s, 3H), 1.40--1.33 (m, 1H), 1.12 (d, *J* = 6.7 Hz, 3H), 0.89 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 210.8, 167.3, 163.1, 162.8, 142.6, 132.1, 123.7, 118.3, 105.8, 96.6, 92.1, 65.8, 46.1, 39.6, 27.0, 26.4, 25.8, 17.8, 16.74, 16.68, 12.0. HRMS calculated for C~21~H~30~O~4~ (M + H)^+^ 347.2217, found (M + H)^+^ 347.2214. HPLC purity: 99.7% (254 nm), *t*~R~ = 8.17 min; 99.6% (220 nm), *t*~R~ = 8.17 min.

General Procedure for the Synthesis of **2c**--**f** {#sec4.3}
----------------------------------------------------

To a solution of **1c** (200 mg, 0.67 mmol) in DMF (4 mL) at 0 °C was added NaH (54 mg, 1.34 mmol) carefully. After stirring for 30 min, appropriate alkyl bromide (1 mmol) in DMF (1 mL) was added dropwise. The resulting mixture was stirred at room temperature until the complete consumption of **1c** (1--7 h). Afterward, the reaction was quenched with water and extracted with EtOAc twice. The organic layer was washed with water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure, and the residue was dissolved in MeOH (10 mL), followed by the addition of concentrated HCl (510 μL, 6 mmol) carefully. The resulting mixture was stirred at room temperature overnight, and the solvent was removed under reduced pressure. The crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc to give the product.

### 1-(2-(Allyloxy)-4,6-dihydroxyphenyl)-2-methylbutan-1-one (**2c**) {#sec4.3.1}

Purified with hexane/EtOAc (85/15) to give the product (157 mg, 0.63 mmol, 93% over two steps) as pale yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 6.11--6.02 (m, 1H), 6.00 (d, *J* = 2.1 Hz, 1H), 5.91 (d, *J* = 2.1 Hz, 1H), 5.86 (br, 1H), 5.42 (d, *J* = 17.2 Hz, 1H), 5.35 (d, *J* = 10.4 Hz, 1H), 4.57 (d, *J* = 5.6 Hz, 2H), 3.69--3.64 (m, 1H), 1.84--1.79 (m, 1H), 1.42--1.35 (m, 1H), 1.13 (d, *J* = 6.7 Hz, 3H), 0.89 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 210.9, 167.2, 163.1, 162.3, 132.1, 119.2, 105.7, 96.9, 92.3, 70.0, 46.1, 27.0, 16.7, 11.9. HRMS calculated for C~14~H~18~O~4~ (M -- H)^−^ 249.1132, found (M -- H)^−^ 249.1102. HPLC purity: 99.7% (254 nm), *t*~R~ = 7.16 min; 99.9% (220 nm), *t*~R~ = 7.16 min.

### 1-(2-(Hexyloxy)-4,6-dihydroxyphenyl)-2-methylbutan-1-one (**2d**) {#sec4.3.2}

Purified with reverse phase C18 silica gel chromatography with H~2~O/MeCN (45/55) to give the product (130 mg, 0.44 mmol, 66% over two steps) as pale solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 6.01 (s, 1H), 5.92 (s, 1H), 3.96 (t, *J* = 6.5 Hz, 2H), 3.74--3.69 (m, 1H), 1.85--1.75 (m, 3H), 1.46--1.33 (m, 7H), 1.14 (d, *J* = 6.8 Hz, 3H), 0.92--0.87 (m, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 210.8, 167.3, 163.2, 163.0, 105.6, 96.6, 91.9, 69.2, 46.0, 31.6, 29.1, 26.8, 26.1, 22.7, 17.0, 14.1, 11.9. HRMS calculated for C~17~H~26~O~4~ (M -- H)^−^ 293.1758, found (M -- H)^−^ 293.1713. HPLC purity: 99.2% (254 nm), *t*~R~ = 7.93 min; 99.9% (220 nm), *t*~R~ = 7.92 min.

### 1-(2,4-Dihydroxy-6-(octyloxy)phenyl)-2-methylbutan-1-one (**2e**) {#sec4.3.3}

Purified with reverse phase C18 silica gel chromatography with H~2~O/MeCN (40/60) to give the product (151 mg, 0.47 mmol, 70% over two steps) as pale yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.33 (br, 1H), 6.01 (d, *J* = 1.5 Hz, 1H), 5.91 (d, *J* = 1.5 Hz, 1H), 3.97 (t, *J* = 6.5 Hz, 2H), 3.74--3.69 (m, 1H), 1.85--1.77 (m, 3H), 1.46--1.28 (m, 11H), 1.14 (d, *J* = 6.8 Hz, 3H), 0.90--0.87 (m, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 210.7, 167.3, 163.2, 163.0, 105.6, 96.6, 91.9, 69.2, 46.1, 31.9, 29.4, 29.3, 29.1, 26.8, 26.4, 22.8, 17.0, 14.2, 11.9. HRMS calculated for C~19~H~30~O~4~ (M + H)^+^ 323.2217, found (M + H)^+^ 323.2213. HPLC purity: 98.8% (254 nm), *t*~R~ = 8.31 min; 99.9% (220 nm), *t*~R~ = 8.31 min.

### (*S*)-1-(2-(Allyloxy)-4,6-dihydroxyphenyl)-2-methylbutan-1-one (**2f**) {#sec4.3.4}

Purified with hexane/EtOAc (85/15) to give the product (152 mg, 0.61 mmol, 90% over two steps) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 6.11--6.02 (m, 1H), 6.00 (d, *J* = 2.1 Hz, 1H), 5.91 (d, *J* = 2.1 Hz, 1H), 5.86 (br, 1H), 5.42 (d, *J* = 17.2 Hz, 1H), 5.35 (d, *J* = 10.4 Hz, 1H), 4.57 (d, *J* = 5.6 Hz, 2H), 3.69--3.64 (m, 1H), 1.84--1.79 (m, 1H), 1.42--1.35 (m, 1H), 1.13 (d, *J* = 6.7 Hz, 3H), 0.89 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 210.8, 167.3, 163.0, 162.3, 132.1, 119.3, 105.7, 96.9, 92.3, 70.1, 46.2, 27.0, 16.7, 11.9. HRMS calculated for C~14~H~18~O~4~ (M -- H)^−^ 249.1132, found (M -- H)^−^ 249.1104. HPLC purity: 99.1% (254 nm), *t*~R~ = 7.17 min; 99.6% (220 nm), *t*~R~ = 7.17 min.

General Procedure for the Synthesis of **3a**--**e** {#sec4.4}
----------------------------------------------------

To a solution of **1d** (152 mg, 1 mmol) in ethanol (2.5 mL) were added pyrrolidine (220 mg, 3.1 mmol) and corresponding aldehyde (6 mmol) successively. The resulting mixture was stirred at 150 °C in a pressure tube for 1 h. Afterward, the solution was diluted with ethyl acetate and the organic layer was washed with 10% HCl, water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc to give the product.

### 7-Hydroxy-2-propylchroman-4-one (**3a**) {#sec4.4.1}

Purified with hexane/EtOAc (87/13) to give the product (85 mg, 0.41 mmol, 41%) as light brown solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 8.13 (br, 1H), 7.79 (d, *J* = 8.6 Hz, 1H), 6.55 (d, *J* = 8.4 Hz, 1H), 6.43 (s, 1H), 4.42 (br, 1H), 2.67--2.63 (m, 2H), 1.85--1.80 (m, 1H), 1.68--1.44 (m, 3H), 0.99--0.95 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 193.0, 164.32, 164.29, 129.5, 114.6, 110.8, 103.4, 78.0, 42.6, 37.1, 18.3, 14.0. HRMS calculated for C~12~H~14~O~3~ (M -- H)^−^ 205.0870, found (M -- H)^−^ 205.0863. HPLC purity: 97.3% (254 nm), *t*~R~ = 6.31 min; 98.6% (220 nm), *t*~R~ = 6.31 min.

### 2-Hexyl-7-hydroxychroman-4-one (**3b**) {#sec4.4.2}

Purified with hexane/EtOAc (90/10) to give the product (92 mg, 0.37 mmol, 37%) as light brown solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.78 (d, *J* = 8.7 Hz, 1H), 6.55 (dd, *J* = 8.6, 1.7 Hz, 1H), 6.44 (d, *J* = 1.7 Hz, 1H), 4.43--4.39 (m, 1H), 2.66--2.63 (m, 2H), 1.87--1.82 (m, 1H), 1.67--1.64 (m, 1H), 1.53--1.30 (m, 8H), 0.90--0.87 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 193.1, 164.34, 164.30, 129.4, 114.6, 110.8, 103.4, 78.3, 42.6, 35.0, 31.8, 29.2, 25.0, 22.7, 14.2. HRMS calculated for C~15~H~20~O~3~ (M -- H)^−^ 247.1340, found (M -- H)^−^ 247.1331. HPLC purity: 98.4% (254 nm), *t*~R~ = 7.06 min; 99.1% (220 nm), *t*~R~ = 7.06 min.

### 2-Heptyl-7-hydroxychroman-4-one (**3c**) {#sec4.4.3}

Purified with hexane/EtOAc (90/10) to give the product (91 mg, 0.35 mmol, 35%) as light brown solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.78 (d, *J* = 8.7 Hz, 1H), 6.55 (dd, *J* = 8.7, 2.3 Hz, 1H), 6.43 (d, *J* = 2.2 Hz, 1H), 4.43--4.39 (m, 1H), 2.69--2.60 (m, 2H), 1.88--1.80 (m, 1H), 1.70--1.63 (m, 1H), 1.53--1.25 (m, 10H), 0.89--0.86 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 193.0, 164.4, 164.3, 129.4, 114.6, 110.9, 103.4, 78.3, 42.6, 35.0, 31.9, 29.5, 29.3, 25.0, 22.8, 14.2. HRMS calculated for C~16~H~22~O~3~ (M -- H)^−^ 261.1496, found (M -- H)^−^ 261.1479. HPLC purity: 95.0% (254 nm), *t*~R~ = 7.28 min; 96.1% (220 nm), *t*~R~ = 7.28 min.

### 7-Hydroxy-2-nonylchroman-4-one (**3d**) {#sec4.4.4}

Purified with hexane/EtOAc (90/10) to give the product (98 mg, 0.33 mmol, 33%) as light brown solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 8.23 (br, 1H), 7.79 (d, *J* = 8.7 Hz, 1H), 6.56 (dd, *J* = 8.7, 2.1 Hz, 1H), 6.43 (d, *J* = 2.1 Hz, 1H), 4.45--4.38 (m, 1H), 2.70--2.61 (m, 2H), 1.88--1.80 (m, 1H), 1.70--1.63 (m, 1H), 1.55--1.25 (m, 14H), 0.89--0.86 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 193.1, 164.4, 129.5, 114.6, 110.9, 103.4, 78.3, 42.5, 35.0, 32.0, 29.7, 29.6, 29.5, 29.4, 25.0, 22.8, 14.2. HRMS calculated for C~18~H~26~O~3~ (M -- H)^−^ 289.1809, found (M -- H)^−^ 289.1787. HPLC purity: 99.1% (254 nm), *t*~R~ = 7.71 min; 99.3% (220 nm), *t*~R~ = 7.71 min.

### 7-Hydroxy-2-phenethylchroman-4-one (**3e**) {#sec4.4.5}

Purified with reverse phase C18 silica gel chromatography with H~2~O/MeCN (45/55) to give the product (54 mg, 0.20 mmol, 20%) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.79 (d, *J* = 8.6 Hz, 1H), 7.27--7.25 (m, 2H), 7.20--7.16 (m, 3H), 6.53 (dd, *J* = 8.7, 1.8 Hz, 1H), 6.45 (d, *J* = 1.7 Hz, 1H), 4.43--4.37 (m, 1H), 2.91--2.76 (m, 2H), 2.71--2.59 (m, 2H), 2.22--2.14 (m, 1H), 2.01--1.94 (m, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 192.7, 164.3, 164.2, 141.0, 129.5, 128.7, 128.6, 126.3, 114.6, 111.0, 103.4, 77.1, 42.6, 36.6, 31.2. HRMS calculated for C~17~H~16~O~3~ (M -- H)^−^ 267.1027, found (M -- H)^−^ 267.1012. HPLC purity: 100% (254 nm), *t*~R~ = 6.69 min; 99.5% (220 nm), *t*~R~ = 6.69 min.

General Procedure for the Synthesis of **3f**, **3k**, and **3l** {#sec4.5}
-----------------------------------------------------------------

To a solution of corresponding MOM-protected acetophenone (196 mg, 1 mmol) in ethanol (2.5 mL) was added DEA (154 mg, 2.1 mmol) and (±)-citronellal (309 mg, 2 mmol) successively. The resulting mixture was stirred at 150 °C in a pressure tube for 1 h. The resulting solution was cooled to room temperature and diluted with EtOAc. The organic layer was washed with 10% HCl aq, water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure and the residue was dissolved in methanol (14 mL), followed by the careful addition of concentrated HCl (340 μL, 4 mmol), and the resulting mixture was stirred at room temperature overnight. Afterward, the solution was concentrated and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc to give the product.

### 2-(2,6-Dimethylhept-5-en-1-yl)-7-hydroxychroman-4-one (**3f**) {#sec4.5.1}

Purified with hexane/EtOAc (90/10) to obtain a mixture of two diastereomers (167 mg, 0.58 mmol, 58% over two steps) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.79 (d, *J* = 8.6 Hz, 2H), 6.55 (d, *J* = 8.7 Hz, 2H), 6.43 (s, 2H), 5.98 (br, 2H), 5.11--5.08 (m, 2H), 4.55--4.50 (m, 2H), 2.69--2.56 (m, 4H), 2.04--1.90 (m, 6H), 1.82--1.69 (m, 2H), 1.68 (s, 6H), 1.60 (s, 6H), 1.44--1.32 (m, 4H), 1.26--1.19 (m, 2H), 0.97--0.94 (m, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 192.95, 192.86, 164.4, 164.32, 164.28, 131.7, 131.6, 129.4, 124.6, 124.5, 114.6, 110.9, 103.4, 76.2, 43.2, 42.9, 42.3, 42.2, 37.5, 36.9, 28.9, 28.5, 25.9, 25.5, 25.4, 20.0, 19.4, 17.8. HRMS calculated for C~18~H~24~O~3~ (M -- H)^−^ 287.1653, found (M -- H)^−^ 287.1632. HPLC purity: 97.8% (254 nm), *t*~R~ = 7.32 min; 98.0% (220 nm), *t*~R~ = 7.32 min.

### 2-(2,6-Dimethylhept-5-en-1-yl)-6-hydroxychroman-4-one (**3k**) {#sec4.5.2}

Purified with hexane/EtOAc (92/8) to obtain a mixture of two diastereomers (216 mg, 0.75 mmol, 75% over two steps) as yellow oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.40 (d, *J* = 3.1 Hz, 2H), 7.07 (dd, *J* = 8.9, 3.1 Hz, 2H), 6.91 (br, 2H), 6.87 (dd, *J* = 8.9, 2.6 Hz, 2H), 5.11--5.08 (m, 2H), 4.51--4.45 (m, 2H), 2.71--2.58 (m, 4H), 2.04--1.72 (m, 8H), 1.68 (s, 6H), 1.60 (s, 6H), 1.45--1.17 (m, 6H), 0.97--0.94 (m, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 194.2, 194.1, 156.44, 156.38, 150.5, 131.61, 131.56, 125.3, 124.61, 124.56, 121.0, 119.4, 119.3, 111.1, 76.6, 76.1, 43.7, 43.4, 42.30, 42.26, 37.5, 36.9, 28.9, 28.6, 25.8, 25.5, 25.4, 20.0, 19.4, 17.8. HRMS calculated for C~18~H~24~O~3~ (M -- H)^−^ 287.1653, found (M -- H)^−^ 287.1613. HPLC purity: 99.8% (254 nm), *t*~R~ = 7.40 min; 99.7% (220 nm), *t*~R~ = 7.38 min.

### 2-(2,6-Dimethylhept-5-en-1-yl)-5-hydroxychroman-4-one (**3l**) {#sec4.5.3}

Purified by reverse phase C18 silica gel chromatography with H~2~O/MeCN (30/70) to obtain a mixture of two diastereomers (170 mg, 0.59 mmol, 59% over two steps) as pale yellow oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 11.69 (s, 2H), 7.33 (t, *J* = 8.3 Hz, 2H), 6.48 (dd, *J* = 8.3, 0.8 Hz, 2H), 6.41 (ddd, *J* = 8.3, 2.2, 0.8 Hz, 2H), 5.11--5.07 (m, 2H), 4.52--4.48 (m, 2H), 2.77--2.62 (m, 4H), 2.07--1.63 (m, 8H), 1.68 (s, 6H), 1.61 (s, 6H), 1.47--1.18 (m, 6H), 0.98--0.95 (m, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 198.8, 198.7, 162.2, 161.84, 161.79, 138.24, 138.23, 131.7, 131.6, 124.54, 124.48, 109.2, 108.4, 107.48, 107.47, 76.2, 75.6, 43.0, 42.7, 42.21, 42.15, 37.5, 36.8, 28.9, 28.6, 25.9, 25.5, 25.4, 20.0, 19.4, 17.8. HRMS calculated for C~18~H~24~O~3~ (M -- H)^−^ 287.1653, found (M -- H)^−^ 287.1604. HPLC purity: 99.9% (254 nm), *t*~R~ = 8.00 min; 100% (220 nm), *t*~R~ = 7.99 min.

(*E*)-3-(6,6-Dimethylbicyclo\[3.1.1\]hept-2-en-2-yl)-1-(2-hydroxy-4-(methoxymethoxy)phenyl)prop-2-en-1-one (**3h**) {#sec4.5.4}
-------------------------------------------------------------------------------------------------------------------

To a solution of **1e** (196 mg, 1 mmol) in ethanol (2.5 mL) were added pyrrolidine (149 mg, 2.1 mmol) and (−)-myrtenal (300 mg, 2 mmol) successively. The resulting mixture was stirred at 75 °C in a pressure tube for 1 h. Afterward, the solution was diluted with ethyl acetate, and the organic layer was washed with 10% HCl, water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc (97/3) to give compound **3h** (160 mg, 0.48 mmol, 48%) as yellow oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 13.37 (s, 1H), 7.75 (d, *J* = 9.0 Hz, 1H), 7.52 (d, *J* = 15.1 Hz, 1H), 6.88 (d, *J* = 15.1 Hz, 1H), 6.61 (d, *J* = 2.4 Hz, 1H), 6.54 (dd, *J* = 8.9, 2.4 Hz, 1H), 6.21 (m, 1H), 5.20 (s, 2H), 3.47 (s, 3H), 2.68--2.67 (m, 1H), 2.55--2.41 (m, 3H), 2.19--2.18 (m, 1H), 1.39 (s, 3H), 1.18 (d, *J* = 9.0 Hz, 1H), 0.80 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 192.9, 166.2, 163.5, 146.5, 145.6, 137.3, 131.3, 116.7, 115.2, 108.1, 104.0, 94.2, 56.5, 41.6, 40.8, 38.1, 33.1, 31.3, 26.3, 21.0. HRMS calculated for C~20~H~24~O~4~ (M + H)^+^ 329.1747, found (M + H)^+^ 329.1735. HPLC purity: 98.8% (254 nm), *t*~R~ = 7.98 min; 98.5% (220 nm), *t*~R~ = 7.98 min.

(*E*)-1-(2,4-Dihydroxyphenyl)-3-(6,6-dimethylbicyclo\[3.1.1\]hept-2-en-2-yl)prop-2-en-1-one (**3g**) {#sec4.5.5}
----------------------------------------------------------------------------------------------------

To a solution of **3h** (130 mg, 0.396 mmol) in methanol (6 mL) was added concentrated HCl (154 μL, 1.78 mmol) dropwise. The resulting mixture was stirred at room temperature for 24 h, after which the solvent was removed. The crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc (90/10) to obtain compound **3g** (100 mg, 0.35 mmol, 89%) as yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 13.56 (s, 1H), 7.72 (d, *J* = 9.5 Hz, 1H), 7.51 (d, *J* = 15.1 Hz, 1H), 6.87 (d, *J* = 15.2 Hz, 1H), 6.43--6.41 (m, 2H), 6.20 (m, 1H), 2.67 (t, *J* = 5.4 Hz, 1H), 2.54--2.41 (m, 3H), 2.18 (br, 1H), 1.38 (s, 3H), 1.18 (d, *J* = 9.0 Hz, 1H), 0.79 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 193.0, 166.2, 163.1, 146.5, 145.8, 137.5, 132.1, 116.6, 114.5, 108.0, 103.8, 41.5, 40.8, 38.1, 33.1, 31.3, 26.3, 21.0. HRMS calculated for C~18~H~20~O~3~ (M -- H)^−^ 283.1340, found (M -- H)^−^ 283.1313. HPLC purity: 99.3% (254 nm), *t*~R~ = 7.48 min; 99.2% (220 nm), *t*~R~ = 7.48 min.

2-(6,6-Dimethylbicyclo\[3.1.1\]hept-2-en-2-yl)-7-(methoxymethoxy)chroman-4-one (**3i**) {#sec4.5.6}
---------------------------------------------------------------------------------------

To a solution of **3h** (60 mg, 0.183 mmol) in ethanol (3 mL) was added sodium acetate (300 mg, 3.6 mmol). The resulting mixture was refluxed for 24 h, after which the solvent was removed. The residue was dissolved in ethyl acetate, and the organic layer was washed with water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc (95/5) to obtain a mixture of two diastereomers **3i** (28 mg, 0.085 mmol, 47%) as clear oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.82--7.79 (m, 2H), 6.66--6.62 (m, 2H), 6.61 (s, 2H), 5.67--5.64 (m, 2H), 5.19 (s, 2H), 5.18 (s, 2H), 4.88--4.77 (m, 2H), 3.47 (s, 3H), 3.46 (s, 3H), 2.82--2.72 (m, 2H), 2.66--2.53 (m, 2H), 2.51--2.38 (m, 3H), 2.34--2.23 (m, 5H), 2.12 (br, 2H), 1.32--1.30 (m, 6H), 1.28--1.14 (m, 2H), 0.87 (s, 3H), 0.74 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 191.6, 191.5, 163.59, 163.58, 163.50, 163.48, 145.4, 145.3, 128.72, 128.67, 122.1, 120.7, 115.9, 115.8, 111.0, 103.63, 103.58, 94.15, 94.14, 80.3, 79.8, 77.4, 56.5, 56.4, 42.6, 42.2, 41.0, 40.9, 40.8, 38.2, 38.0, 31.8, 31.7, 31.38, 31.36, 26.24. 26.20, 21.40, 21.35. HRMS calculated for C~20~H~24~O~4~ (M + H)^+^ 329.1747, found (M + H)^+^ 329.1736. HPLC purity: 99.6% (49.0% + 50.6%) (254 nm), *t*~R~ = 7.66 and 7.68 min; 98.8% (220 nm), *t*~R~ = 7.66 min. The split HPLC product peaks further supported the product is a mixture of two diastereomers (see [Supporting Information](#notes-2){ref-type="notes"} for the details of HPLC trace).

2-(6,6-Dimethylbicyclo\[3.1.1\]hept-2-en-2-yl)-7-hydroxychroman-4-one (**3j**) {#sec4.5.7}
------------------------------------------------------------------------------

To a solution of **3i** (38 mg, 0.116 mmol) in methanol (2 mL) was added concentrated HCl (45 μL, 0.52 mmol) carefully. The resulting mixture was stirred at room temperature for 24 h, after which the solvent was removed. The crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc (85/15) to obtain a mixture of two diastereomers **3j** (30 mg, 0.106 mmol, 90%) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.79--7.76 (m, 2H), 7.67 (br, 2H), 6.54--6.51 (m, 2H), 6.43--6.42 (m, 2H), 5.65--5.64 (m, 2H), 4.87--4.77 (m, 2H), 2.84--2.75 (m, 2H), 2.67--2.54 (m, 2H), 2.49--2.22 (m, 8H), 2.11 (br, 2H), 2.00 (br, 2H), 1.31--1.29 (m, 6H), 1.26--1.12 (m, 2H), 0.85 (s, 3H), 0.73 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 192.39, 192.36, 164.0, 163.7, 145.3, 145.2, 129.4, 129.3, 122.2, 120.9, 114.89, 114.86, 110.62, 110.61, 103.5, 80.1, 79.6, 77.4, 77.1, 42.6, 42.2, 40.9, 40.83, 40.79, 40.7, 38.2, 38.0, 31.8, 31.7, 31.39, 31.36, 26.24, 26.20, 21.38, 21.36. HRMS calculated for C~18~H~20~O~3~ (M -- H)^−^ 283.1340, found (M -- H)^−^ 283.1310. HPLC purity: 99.4% (49.7% + 49.7%) (254 nm), *t*~R~ = 7.09 and 7.11 min; 99.6% (50.6% + 49.0%) (220 nm), *t*~R~ = 7.09 and 7.11 min. The split HPLC product peaks further supported the product is a mixture of two diastereomers (see [Supporting Information](#notes-2){ref-type="notes"} for the details of HPLC trace).

General Procedure for the Synthesis of **4a**--**d** {#sec4.6}
----------------------------------------------------

To a solution of appropriate 4-chromanone **3a**--**d** (0.22 mmol) in methanol (3 mL) was added sodium borohydride (16.6 mg, 0.44 mmol) every 1.5 h for a total of 9 h. The resulting mixture was allowed to stir at room temperature overnight. The mixture was cooled to 0 °C, quenched with saturated NH~4~Cl aq carefully, and extracted with EtOAc twice. The combined organic layer was washed with water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc to give the product.

### 2-Propylchroman-4,7-diol (**4a**) {#sec4.6.1}

Purified with hexane/EtOAc (85/15) to give the product (29 mg, 0.14 mmol, 64%) as light brown oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.19 (d, *J* = 8.4 Hz, 1H), 6.64 (br, 1H), 6.34 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.24 (d, *J* = 2.4 Hz, 1H), 4.83--4.79 (m, 1H), 4.04--4.98 (m, 1H), 2.68 (br, 1H), 2.33 (br, 1H), 2.23--2.17 (m, 1H), 1.74--1.62 (m, 2H), 1.59--1.39 (m, 3H), 0.94 (t, *J* = 7.2 Hz, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 156.6, 155.8, 128.3, 118.3, 108.6, 103.1, 75.2, 65.5, 38.0, 37.6, 18.4, 14.1. HRMS calculated for C~12~H~16~O~3~ (M -- H~2~O + H)^+^ 191.1067, found (M -- H~2~O + H)^+^ 191.1058. HPLC purity: 95.3% (220 nm), *t*~R~ = 5.91 min.

### 2-Hexylchroman-4,7-diol (**4b**) {#sec4.6.2}

Purified with hexane/EtOAc (85/15) to give the product (42 mg, 0.17 mmol, 77%) as light brown oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.18 (d, *J* = 8.4 Hz, 1H), 6.72 (br, 1H), 6.34 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.25 (d, *J* = 2.4 Hz, 1H), 4.82--4.80 (m, 1H), 4.03--3.97 (m, 1H), 2.75--2.73 (m, 1H), 2.43 (br, 1H), 2.24--2.19 (m, 1H), 1.76--1.52 (m, 3H), 1.50--1.30 (m, 7H), 0.90--0.87 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 156.5, 155.8, 128.3, 118.3, 108.6, 103.1, 75.5, 65.6, 38.0, 35.5, 31.9, 29.3, 25.2, 22.7, 14.2. HRMS calculated for C~15~H~22~O~3~ (M -- H~2~O + H)^+^ 233.1536, found (M -- H~2~O + H)^+^ 233.1534. HPLC purity: 97.8% (220 nm), *t*~R~ = 6.73 min.

### 2-Heptylchroman-4,7-diol (**4c**) {#sec4.6.3}

Purified with hexane/EtOAc (85/15) to give the product (39 mg, 0.15 mmol, 68%) as light brown oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.25 (d, *J* = 8.4 Hz, 1H), 6.39 (dd, *J* = 8.4, 2.5 Hz, 1H), 6.26 (d, *J* = 2.4 Hz, 1H), 5.82 (br, 1H), 4.88--4.82 (m, 1H), 4.07--4.01 (m, 1H), 2.29--2.23 (m, 1H), 2.11--2.09 (m, 1H), 1.92 (br, 1H), 1.78--1.38 (m, 5H), 1.33--1.28 (m, 9H), 0.90--0.87 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 156.6, 155.9, 128.3, 118.5, 108.5, 103.1, 75.5, 65.6, 38.2, 35.6, 32.0, 29.7, 29.4, 25.2, 22.8, 14.2. HRMS calculated for C~16~H~24~O~3~ (M -- H)^−^ 263.1653, found (M -- H)^−^ 263.1632. HPLC purity: 95.7% (220 nm), *t*~R~ = 6.97 min.

### 2-Nonylchroman-4,7-diol (**4d**) {#sec4.6.4}

Purified with hexane/EtOAc (85/15) to give the product (52 mg, 0.18 mmol, 81%) as light brown oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.19 (d, *J* = 8.4 Hz, 1H), 6.54 (br, 1H), 6.34 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.25 (d, *J* = 2.4 Hz, 1H), 4.83--4.81 (m, 1H), 4.02--3.99 (m, 1H), 2.61--2.59 (m, 1H), 2.32 (br, 1H), 2.25--2.20 (m, 1H), 1.75--1.53 (m, 2H), 1.49--1.27 (m, 14H), 0.90--0.87 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 156.5, 155.8, 128.3, 118.3, 108.6, 103.1, 75.5, 65.6, 38.1, 35.5, 32.0, 29.72, 29.70, 29.5, 25.2, 22.8, 14.2. HRMS calculated for C~18~H~28~O~3~ (M -- H)^−^ 291.1966, found (M -- H)^−^ 291.1926. HPLC purity: 97.7% (220 nm), *t*~R~ = 7.41 min.

General Procedure for the Synthesis of **5a**--**l** {#sec4.7}
----------------------------------------------------

To a solution of **1h** (256 mg, 1 mmol) in ethanol (2.5 mL) were added DEA (154 mg, 2.1 mmol) and corresponding aldehyde (2 mmol) successively. The resulting mixture was stirred at 150 °C in a pressure tube for 1 h. Afterward, the solution was diluted with ethyl acetate and the organic layer was washed with 10% HCl, water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc to give the MOM-protected product.

To a solution of appropriate MOM-protected compound (0.22 mmol) in methanol (4 mL) was added concentrated HCl (172 μL, 1.98 mmol) at room temperature, and the resulting mixture was stirred overnight. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc to give the corresponding deprotected product.

### 5,7-Bis(methoxymethoxy)-2-propylchroman-4-one (**5a**) {#sec4.7.1}

Purified with hexane/EtOAc (87/13) to give the product (195 mg, 0.63 mmol, 63%) as clear oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 6.37 (s, 1H), 6.29 (s, 1H), 5.24 (s, 2H), 5.16 (s, 2H), 4.39--4.35 (m, 1H), 3.51 (s, 3H), 3.46 (s, 3H), 2.64--2.53 (m, 2H), 1.83--1.79 (m, 1H), 1.66--1.43 (m, 3H), 0.96 (t, *J* = 7.1 Hz, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 190.1, 164.8, 163.2, 159.5, 107.5, 97.8, 97.2, 95.1, 94.1, 77.3, 56.64, 56.57, 44.3, 37.0, 18.3, 14.0. HRMS calculated for C~16~H~22~O~6~ (M + H)^+^ 311.1489, found (M + H)^+^ 311.1481. HPLC purity: 98.0% (254 nm), *t*~R~ = 6.78 min; 96.3% (220 nm), *t*~R~ = 6.78 min.

### 5,7-Dihydroxy-2-propylchroman-4-one (**5b**) {#sec4.7.2}

Purified with hexane/EtOAc (85/15) to give the product (46 mg, 0.207 mmol, 94%) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 12.03 (s, 1H), 7.24 (br, 1H), 5.97 (s, 1H), 5.93 (s, 1H), 4.41--4.36 (m, 1H), 2.73--2.57 (m, 2H), 1.86--1.79 (m, 1H), 1.69--1.42 (m, 3H), 0.97 (t, *J* = 7.2 Hz, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 197.0, 165.3, 164.2, 163.7, 103.2, 96.5, 95.5, 41.6, 36.9, 18.2, 14.0. HRMS calculated for C~12~H~14~O~4~ (M -- H)^−^ 221.0819, found (M -- H)^−^ 221.0802. HPLC purity: 96.7% (254 nm), *t*~R~ = 6.54 min; 100% (220 nm), *t*~R~ = 6.54 min.

### 2-Hexyl-5,7-bis(methoxymethoxy)chroman-4-one (**5c**) {#sec4.7.3}

Purified with hexane/EtOAc (90/10) to give the product (220 mg, 0.63 mmol, 63%) as clear oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 6.37 (s, 1H), 6.30 (s, 1H), 5.24 (s, 2H), 5.16 (s, 2H), 4.39--4.32 (m, 1H), 3.51 (s, 3H), 3.47 (s, 3H), 2.65--2.53 (m, 2H), 1.84--1.77 (m, 1H), 1.67--1.60 (m, 1H), 1.55--1.30 (m, 8H), 0.90--0.87 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 190.0, 164.8, 163.2, 159.5, 107.5, 97.8, 97.3, 95.1, 94.1, 77.6, 56.6, 56.5, 44.3, 34.9, 31.8, 29.2, 24.9, 22.7, 14.2. HRMS calculated for C~19~H~28~O~6~ (M + H)^+^ 353.1959, found (M + H)^+^ 353.1954. HPLC purity: 99.5% (254 nm), *t*~R~ = 7.49 min; 99.3% (220 nm), *t*~R~ = 7.49 min.

### 2-Hexyl-5,7-dihydroxychroman-4-one (**5d**) {#sec4.7.4}

Purified with hexane/EtOAc (85/15) to give the product (44 mg, 0.165 mmol, 75%) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 12.02 (s, 1H), 6.99 (br, 1H), 5.96 (d, *J* = 1.9 Hz, 1H), 5.93 (d, *J* = 1.9 Hz, 1H), 4.40--4.33 (m, 1H), 2.72--2.57 (m, 2H), 1.86--1.78 (m, 1H), 1.69--1.62 (m, 1H), 1.54--1.30 (m, 8H), 0.90--0.87 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 197.0, 165.3, 164.2, 163.7, 103.2, 96.5, 95.5, 77.7, 41.6, 34.9, 31.8, 29.1, 24.9, 22.7, 14.2. HRMS calculated for C~15~H~20~O~4~ (M -- H)^−^ 263.1289, found (M -- H)^−^ 263.1264. HPLC purity: 97.9% (254 nm), *t*~R~ = 7.26 min; 99.1% (220 nm), *t*~R~ = 7.26 min.

### 2-Heptyl-5,7-bis(methoxymethoxy)chroman-4-one (**5e**) {#sec4.7.5}

Purified with hexane/EtOAc (90/10) to give the product (220 mg, 0.60 mmol, 60%) as clear oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 6.37 (s, 1H), 6.29 (s, 1H), 5.24 (s, 2H), 5.16 (s, 2H), 4.38--4.31 (m, 1H), 3.51 (s, 3H), 3.46 (s, 3H), 2.64--2.52 (m, 2H), 1.85--1.76 (m, 1H), 1.68--1.59 (m, 1H), 1.54--1.27 (m, 10H), 0.89--0.86 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 190.0, 164.8, 163.2, 159.6, 107.5, 97.8, 97.3, 95.1, 94.2, 77.6, 56.64, 56.57, 44.3, 34.9, 31.9, 29.5, 29.3, 25.0, 22.8, 14.2. HRMS calculated for C~20~H~30~O~6~ (M + H)^+^ 367.2115, found (M + H)^+^ 367.2114. HPLC purity: 99.6% (254 nm), *t*~R~ = 7.69 min; 98.8% (220 nm), *t*~R~ = 7.69 min.

### 2-Heptyl-5,7-dihydroxychroman-4-one (**5f**) {#sec4.7.6}

Purified with hexane/EtOAc (90/10) to give the product (49 mg, 0.176 mmol, 80%) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 12.03 (s, 1H), 6.57 (br, 1H), 5.96 (s, 1H), 5.93 (s, 1H), 4.39--4.34 (m, 1H), 2.72--2.57 (m, 2H), 1.86--1.79 (m, 1H), 1.69--1.62 (m, 1H), 1.54--1.26 (m, 10H), 0.90--0.87 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 196.9, 165.0, 164.3, 163.6, 103.3, 96.5, 95.4, 77.8, 41.7, 34.9, 31.9, 29.4, 29.3, 25.0, 22.8, 14.2. HRMS calculated for C~16~H~22~O~4~ (M -- H)^−^ 277.1445, found (M -- H)^−^ 277.1420. HPLC purity: 98.6% (254 nm), *t*~R~ = 7.47 min; 98.8% (220 nm), *t*~R~ = 7.47 min.

### 5,7-Bis(methoxymethoxy)-2-nonylchroman-4-one (**5g**) {#sec4.7.7}

Purified with hexane/EtOAc (90/10) to give the product (218 mg, 0.55 mmol, 55%) as clear oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 6.37 (s, 1H), 6.29 (s, 1H), 5.24 (s, 2H), 5.16 (s, 2H), 4.37--4.31 (m, 1H), 3.51 (s, 3H), 3.47 (s, 3H), 2.64--2.53 (m, 2H), 1.81--1.76 (m, 1H), 1.67--1.59 (m, 1H), 1.54--1.26 (m, 14H), 0.89--0.85 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 190.1, 164.8, 163.2, 159.6, 107.5, 97.8, 97.3, 95.1, 94.2, 77.6, 56.64, 56.57, 44.3, 34.9, 32.0, 29.63, 29.63, 29.5, 29.4, 25.0, 22.8, 14.2. HRMS calculated for C~22~H~34~O~6~ (M + H)^+^ 395.2428, found (M + H)^+^ 395.2407. HPLC purity: 99.9% (254 nm), *t*~R~ = 8.09 min; 99.5% (220 nm), *t*~R~ = 8.09 min.

### 5,7-Dihydroxy-2-nonylchroman-4-one (**5h**) {#sec4.7.8}

Purified with hexane/EtOAc (90/10) to give the product (55 mg, 0.18 mmol, 82%) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 12.05 (s, 1H), 5.95 (s, 1H), 5.92 (s, 1H), 5.44 (br, 1H), 4.40--4.35 (m, 1H), 2.72--2.58 (m, 2H), 1.86--1.80 (m, 1H), 1.69--1.61 (m, 1H), 1.54--1.26 (m, 14H), 0.90--0.88 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 197.1, 165.4, 164.2, 163.7, 103.2, 96.5, 95.5, 77.7, 41.6, 34.8, 32.0, 29.62, 29.58, 29.5, 29.4, 24.9, 22.8, 14.2. HRMS calculated for C~18~H~26~O~4~ (M -- H)^−^ 305.1758, found (M -- H)^−^ 305.1719. HPLC purity: 99.7% (254 nm), *t*~R~ = 7.87 min; 99.2% (220 nm), *t*~R~ = 7.87 min.

### 2-(2,6-Dimethylhept-5-en-1-yl)-5,7-bis(methoxymethoxy)chroman-4-one (**5i**) {#sec4.7.9}

Purified with hexane/EtOAc (90/10) to obtain a mixture of two diastereomers (275 mg, 0.70 mmol, 70%) as clear oil. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 6.35 (s, 2H), 6.27 (s, 2H), 5.22 (s, 4H), 5.14 (s, 4H), 5.07--5.05 (m, 2H), 4.46--4.41 (m, 2H), 3.49 (s, 6H), 3.44 (s, 6H), 2.61--2.45 (m, 4H), 1.99--1.68 (m, 8H), 1.65 (s, 6H), 1.57 (s, 6H), 1.41--1.14 (m, 6H), 0.93--0.91 (m, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 189.9, 189.8, 164.72, 164.67, 163.1, 159.49, 159.48, 131.5, 131.4, 124.54, 124.48, 107.5, 97.8, 97.22, 97.21, 95.0, 94.1, 76.1, 75.5, 56.53, 56.46, 44.9, 44.5, 42.11, 42.06, 37.4, 36.8, 28.7, 28.4, 25.8, 25.4, 25.3, 19.9, 19.4, 17.7. HRMS calculated for C~22~H~32~O~6~ (M + H)^+^ 393.2272, found (M + H)^+^ 393.2263. HPLC purity: 98.8% (254 nm), *t*~R~ = 7.71 min; 98.4% (220 nm), *t*~R~ = 7.71 min.

### 2-(2,6-Dimethylhept-5-en-1-yl)-5,7-dihydroxychroman-4-one (**5j**) {#sec4.7.10}

Purified with hexane/EtOAc (90/10) to obtain a mixture of two diastereomers (54 mg, 0.176 mmol, 80%) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 12.02 (s, 2H), 7.25 (br, 2H), 5.97 (s, 2H), 5.94 (s, 2H), 5.09--5.08 (m, 2H), 4.51--4.46 (m, 2H), 2.73--2.56 (m, 4H), 2.04--1.70 (m, 8H), 1.68 (s, 6H), 1.60 (s, 6H), 1.53--1.32 (m, 4H), 1.25--1.18 (m, 2H), 0.98--0.94 (m, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 197.1, 197.0, 165.4, 164.2, 163.67, 163.65, 131.72, 131.67, 124.54, 124.48, 103.2, 96.6, 95.62, 95.60, 76.3, 75.7, 42.3, 42.14, 42.08, 41.9, 37.5, 36.8, 28.9, 28.5, 25.8, 25.5, 25.4, 20.0, 19.4, 17.8. HRMS calculated for C~18~H~24~O~4~ (M -- H)^−^ 303.1602, found (M -- H)^−^ 303.1564. HPLC purity: 98.4% (254 nm), *t*~R~ = 7.50 min; 98.4% (220 nm), *t*~R~ = 7.50 min.

### 2-Cyclopentyl-5,7-dihydroxychroman-4-one (**5k**) {#sec4.7.11}

Purified with hexane/EtOAc (85/15) to give the product (174 mg, 0.70 mmol, 70% over two steps) as white solid. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ (ppm) 12.12 (s, 1H), 10.73 (s, 1H), 5.83 (s, 2H), 4.26--4.20 (m, 1H), 2.80--2.73 (m, 1H), 2.61--2.56 (m, 1H), 2.18--2.12 (m, 1H), 1.84--1.78 (m, 1H), 1.72--1.42 (m, 6H), 1.32--1.27 (m, 1H). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ (ppm) 196.4, 166.5, 163.4, 163.0, 101.8, 95.6, 94.8, 80.7, 43.3, 40.1, 28.3, 27.7, 25.0, 24.9. HRMS calculated for C~14~H~16~O~4~ (M -- H)^−^ 247.0976, found (M -- H)^−^ 247.0954. HPLC purity: 99.6% (254 nm), *t*~R~ = 6.84 min; 99.6% (220 nm), *t*~R~ = 6.84 min.

### 2-Cyclohexyl-5,7-dihydroxychroman-4-one (**5l**) {#sec4.7.12}

Purified with hexane/EtOAc (85/15) to give the product (168 mg, 0.64 mmol, 64% over two steps) as white solid. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ (ppm) 12.12 (s, 1H), 10.74 (s, 1H), 5.84 (s, 2H), 4.24--4.18 (m, 1H), 2.85--2.77 (m, 1H), 2.55--2.51 (m, 1H), 1.91--1.88 (m, 1H), 1.75--1.63 (m, 5H), 1.28--1.01 (m, 5H). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ (ppm) 196.7, 166.5, 163.4, 163.0, 101.8, 95.6, 94.7, 80.9, 40.9, 38.3, 27.58, 27.56, 25.9, 25.43, 25.36. HRMS calculated for C~15~H~18~O~4~ (M -- H)^−^ 261.1132, found (M -- H)^−^ 261.1106. HPLC purity: 99.1% (254 nm), *t*~R~ = 7.05 min; 99.5% (220 nm), *t*~R~ = 7.05 min.

(*E*)-3-(6,6-Dimethylbicyclo\[3.1.1\]hept-2-en-2-yl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one (**5m**) {#sec4.7.13}
-------------------------------------------------------------------------------------------------------

To a solution of **1h** (256 mg, 1 mmol) in ethanol (2.5 mL) were added DEA (154 mg, 2.1 mmol) and (−)-myrtenal (300 mg, 2 mmol) successively. The resulting mixture was stirred at 150 °C in a pressure tube for 4 h. Afterward, the solution was diluted with ethyl acetate and the organic layer was washed with 10% HCl, water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure, and the residue was dissolved in methanol (15 mL), followed by the addition of concentrated HCl (765 μL, 9 mmol) dropwise. The resulting mixture was stirred at room temperature for 16 h, after which the solvent was removed. The crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc (75/25) to obtain compound **5m** (102 mg, 0.34 mmol, 34%) as yellow solid. ^1^H NMR (400 MHz, CD~3~OD): δ (ppm) 7.55 (d, *J* = 15.4 Hz, 1H), 7.38 (d, *J* = 15.4 Hz, 1H), 6.11 (s, 1H), 5.81 (s, 2H), 2.65--2.64 (m, 1H), 2.57--2.47 (m, 3H), 2.18--2.17 (m, 1H), 1.38 (s, 3H), 1.18 (d, *J* = 9.0 Hz, 1H), 0.82 (s, 3H). ^13^C NMR (100 MHz, CD~3~OD): δ (ppm) 194.6, 166.2, 165.9, 148.3, 144.2, 135.5, 125.5, 105.9, 96.0, 42.9, 42.0, 38.7, 33.7, 32.0, 26.6, 21.2. HRMS calculated for C~18~H~20~O~4~ (M -- H)^−^ 299.1289, found (M -- H)^−^ 299.1240. HPLC purity: 99.6% (254 nm), *t*~R~ = 7.29 min; 99.9% (220 nm), *t*~R~ = 7.29 min.

2-(6,6-Dimethylbicyclo\[3.1.1\]hept-2-en-2-yl)-5,7-dihydroxychroman-4-one (**5n**) {#sec4.7.14}
----------------------------------------------------------------------------------

To a suspension of **5m** (57 mg, 0.19 mmol) in ethanol (2.5 mL) was added catalytic amount of concentrated HCl. The resulting mixture was stirred at 150 °C under microwave irradiation for 30 min. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc (75/25) to obtain a mixture of two diastereomers **5n** (41 mg, 0.136 mmol, 72%) as pale yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 12.05 (br, 2H), 5.98--5.94 (m, 4H), 5.68--5.67 (m, 2H), 4.86--4.75 (m, 2H), 2.89--2.80 (m, 2H), 2.69--2.55 (m, 2H), 2.53--2.45 (m, 2H), 2.43--2.26 (m, 6H), 2.16--2.15 (m, 2H), 1.34--1.33 (m, 6H), 1.29--1.16 (m, 2H), 0.88 (s, 3H), 0.78 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 196.82, 196.80, 165.2, 164.2, 163.5, 145.0, 144.8, 122.4, 121.2, 103.21, 103.18, 96.55, 96.54, 95.7, 79.5, 79.0, 42.5, 42.2, 40.9, 40.8, 39.8, 39.7, 38.2, 38.0, 31.7, 31.6, 31.4, 31.3, 26.20, 26.16, 21.4, 21.3. HRMS calculated for C~18~H~20~O~4~ (M -- H)^−^ 299.1289, found (M -- H)^−^ 299.1247. HPLC purity: 99.7% (254 nm), *t*~R~ = 7.53 min; 99.9% (220 nm), *t*~R~ = 7.52 min.

General Procedure for the Synthesis of **6a**--**f** {#sec4.8}
----------------------------------------------------

To a suspension of corresponding hydroxyamine (0.8 mmol) in ethanol (1 mL) was added pyridine (64 mg, 0.8 mmol). After stirring at room temperature for 15 min, the solution of appropriate 4-chromanone (0.1 mmol) in ethanol (2 mL) was added. The resulting mixture was stirred for 26--72 h at room temperature, after which the solvent was removed. EtOAc was added to the residue, and the organic layer was washed with water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc to give oxime compound.

### 5,7-Dihydroxy-2-nonylchroman-4-one oxime (**6a**) {#sec4.8.1}

Purified with hexane/EtOAc (85/15) to give the product (29 mg, 0.09 mmol, 90%) as white solid. ^1^H NMR (400 MHz, CD~3~OD): δ (ppm) 5.89 (d, *J* = 2.3 Hz, 1H), 5.85 (d, *J* = 2.3 Hz, 1H), 3.99--3.93 (m, 1H), 3.24 (dd, *J* = 17.1, 3.5 Hz, 1H), 2.32 (dd, *J* = 17.1, 11.4 Hz, 1H), 1.79--1.70 (m, 1H), 1.67--1.59 (m, 1H), 1.57--1.30 (m, 14H), 0.92--0.88 (m, 3H). ^13^C NMR (100 MHz, CD~3~OD): δ (ppm) 161.5, 160.7, 159.5, 154.7, 98.8, 97.3, 96.2, 76.2, 36.1, 33.1, 30.69, 30.68, 30.62, 30.5, 29.0, 26.2, 23.7, 14.5. HRMS calculated for C~18~H~27~NO~4~ (M -- H)^−^ 320.1867, found (M -- H)^−^ 320.1818. HPLC purity: 99.9% (254 nm), *t*~R~ = 7.62 min; 99.5% (220 nm), *t*~R~ = 7.62 min.

### 5,7-Dihydroxy-2-nonylchroman-4-one *O*-Methyloxime (**6b**) {#sec4.8.2}

Purified with hexane/EtOAc (90/10) to give the product (27 mg, 0.081 mmol, 81%) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 10.96 (s, 1H), 6.04 (d, *J* = 2.3 Hz, 1H), 5.96 (d, *J* = 2.3 Hz, 1H), 5.60 (br, 1H), 4.03--3.98 (m, 1H), 3.94 (s, 3H), 3.18 (dd, *J* = 17.2, 3.0 Hz, 1H), 2.36 (dd, *J* = 17.2, 11.6 Hz, 1H), 1.82--1.73 (m, 1H), 1.66--1.57 (m, 1H), 1.54--1.27 (m, 14H), 0.90--0.86 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 159.7, 159.1, 158.7, 154.1, 98.3, 97.0, 95.8, 75.1, 62.5, 35.0, 32.0, 29.67, 29.66, 29.59, 29.5, 28.6, 25.2, 22.8, 14.3. HRMS calculated for C~19~H~29~NO~4~ (M -- H)^−^ 334.2024, found (M -- H)^−^ 334.1977. HPLC purity: 99.8% (254 nm), *t*~R~ = 8.13 min; 99.1% (220 nm), *t*~R~ = 8.13 min.

### 5,7-Dihydroxy-2-nonylchroman-4-one *O*-Benzyloxime (**6c**) {#sec4.8.3}

Purified with hexane/EtOAc (92/8) to give the product (34 mg, 0.083 mmol, 83%) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 10.89 (s, 1H), 7.39--7.31 (m, 5H), 6.01 (d, *J* = 2.4 Hz, 1H), 5.94 (d, *J* = 2.3 Hz, 1H), 5.45 (br, 1H), 5.12 (s, 2H), 4.02--3.96 (m, 1H), 3.22 (dd, *J* = 17.2, 3.0 Hz, 1H), 2.40 (dd, *J* = 17.2, 11.6 Hz, 1H), 1.80--1.72 (m, 1H), 1.65--1.57 (m, 1H), 1.54--1.27 (m, 14H), 0.91--0.87 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 159.7, 159.1, 158.7, 154.5, 137.0, 128.72, 128.68, 128.5, 98.4, 96.9, 95.8, 76.7, 75.0, 35.0, 32.0, 29.67, 29.65, 29.58, 29.4, 28.9, 25.1, 22.8, 14.3. HRMS calculated for C~25~H~33~NO~4~ (M + H)^+^ 412.2482, found (M + H)^+^ 412.2472. HPLC purity: 99.1% (254 nm), *t*~R~ = 8.36 min; 98.7% (220 nm), *t*~R~ = 8.37 min.

### 5,7-Dihydroxy-2-propylchroman-4-one Oxime (**6d**) {#sec4.8.4}

Purified with hexane/EtOAc (83/17) to give the product (20 mg, 0.084 mmol, 84%) as white solid. ^1^H NMR (400 MHz, CD~3~OD): δ (ppm) 5.90 (s, 1H), 5.85 (s, 1H), 3.98 (br, 1H), 3.24 (d, *J* = 17.0, 1H), 2.33 (dd, *J* = 17.0, 11.4 Hz, 1H), 1.75--1.72 (m, 1H), 1.63--1.47 (m, 3H), 1.0--0.96 (m, 3H). ^13^C NMR (100 MHz, CD~3~OD): δ (ppm) 161.5, 160.7, 159.5, 154.8, 98.8, 97.3, 96.2, 76.0, 38.2, 28.0, 19.4, 14.3. HRMS calculated for C~12~H~15~NO~4~ (M -- H)^−^ 236.0928, found (M -- H)^−^ 236.0908. HPLC purity: 99.9% (254 nm), *t*~R~ = 6.35 min; 100% (220 nm), *t*~R~ = 6.34 min.

### 2-Hexyl-5,7-dihydroxychroman-4-one Oxime (**6e**) {#sec4.8.5}

Purified with hexane/EtOAc (86/14) to give the product (22 mg, 0.08 mmol, 80%) as white solid. ^1^H NMR (400 MHz, CD~3~OD): δ (ppm) 5.90 (d, *J* = 2.3 Hz, 1H), 5.85 (d, *J* = 2.3 Hz, 1H), 3.97--3.91 (m, 1H), 3.24 (dd, *J* = 17.1, 3.1 Hz, 1H), 2.32 (dd, *J* = 17.1, 11.4 Hz, 1H), 1.78--1.69 (m, 1H), 1.65--1.49 (m, 2H), 1.45--1.32 (m, 7H), 0.92--0.89 (m, 3H). ^13^C NMR (100 MHz, CD~3~OD): δ (ppm) 161.4, 160.6, 159.5, 154.7, 98.8, 97.3, 96.2, 76.2, 36.0, 32.9, 30.3, 29.0, 26.2, 23.6, 14.4. HRMS calculated for C~15~H~21~NO~4~ (M -- H)^−^ 278.1398, found (M -- H)^−^ 278.1354. HPLC purity: 99.8% (254 nm), *t*~R~ = 7.02 min; 99.9% (220 nm), *t*~R~ = 7.01 min.

### 2-Heptyl-5,7-dihydroxychroman-4-one Oxime (**6f**) {#sec4.8.6}

Purified with hexane/EtOAc (90/10) to give the product (25 mg, 0.085 mmol, 85%) as white solid. ^1^H NMR (400 MHz, CD~3~OD): δ (ppm) 5.90 (s, 1H), 5.85 (s, 1H), 3.95 (br, 1H), 3.24 (d, *J* = 17.0 Hz, 1H), 2.32 (dd, *J* = 17.0, 11.4 Hz, 1H), 1.75--1.73 (m, 1H), 1.63--1.33 (m, 11H), 0.90 (br, 3H). ^13^C NMR (100 MHz, CD~3~OD): δ (ppm) 161.5, 160.7, 159.5, 154.7, 98.8, 97.3, 96.2, 76.2, 36.0, 33.0, 30.6, 30.3, 29.0, 26.2, 23.7, 14.4. HRMS calculated for C~16~H~23~NO~4~ (M -- H)^−^ 292.1554, found (M -- H)^−^ 292.1512. HPLC purity: 99.9% (254 nm), *t*~R~ = 7.22 min; 99.8% (220 nm), *t*~R~ = 7.22 min.

General Procedure for the Synthesis of **7a**--**c** {#sec4.9}
----------------------------------------------------

To a solution of **1e** (196 mg, 1 mmol) in ethanol (2.5 mL) were added pyrrolidine (149 mg, 2.1 mmol) and corresponding cycloketone (2 mmol) successively. The resulting mixture was stirred at 150 °C in a pressure tube for 2--16 h. The resulting solution was cooled to room temperature, and concentrated HCl (1.02 mL, 12 mmol) was added. The resulting mixture was then stirred at room temperature overnight. Afterward, the solution was diluted with EtOAc, and the organic layer was washed with water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc to give the product.

### 7-Hydroxyspiro\[chroman-2,1′-cyclopentan\]-4-one (**7a**) {#sec4.9.1}

Purified with hexane/EtOAc (90/10) to give the product (170 mg, 0.78 mmol, 78% over two steps) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.78 (d, *J* = 8.6 Hz, 1H), 7.12 (br, 1H), 6.49 (dd, *J* = 8.6, 2.3 Hz, 1H), 6.36 (d, *J* = 2.3 Hz, 1H), 2.78 (s, 2H), 2.09--2.04 (m, 2H), 1.87--1.83 (m, 2H), 1.72--1.59 (m, 4H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 192.5, 163.7, 162.8, 129.2, 114.9, 110.1, 104.0, 90.5, 46.8, 37.7, 24.0. HRMS calculated for C~13~H~14~O~3~ (M -- H)^−^ 217.0870, found (M -- H)^−^ 217.0854. HPLC purity: 99.1% (254 nm), *t*~R~ = 6.26 min; 98.7% (220 nm), *t*~R~ = 6.26 min.

### 7-Hydroxyspiro\[chroman-2,1′-cyclohexan\]-4-one (**7b**) {#sec4.9.2}

Purified with hexane/EtOAc (90/10) to give the product (207 mg, 0.89 mmol, 89% over two steps) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.77 (d, *J* = 8.6 Hz, 1H), 7.45 (br, 1H), 6.50 (dd, *J* = 8.6, 2.2 Hz, 1H), 6.42 (d, *J* = 2.2 Hz, 1H), 2.66 (s, 2H), 1.99--1.96 (m, 2H), 1.72--1.59 (m, 3H), 1.50--1.44 (m, 4H), 1.34--1.25 (m, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 192.6, 164.0, 162.2, 129.0, 114.6, 110.1, 103.9, 80.5, 47.9, 35.0, 25.3, 21.6. HRMS calculated for C~14~H~16~O~3~ (M -- H)^−^ 231.1027, found (M -- H)^−^ 231.1007. HPLC purity: 98.2% (254 nm), *t*~R~ = 6.47 min; 98.8% (220 nm), *t*~R~ = 6.47 min.

### 7-Hydroxyspiro\[chroman-2,1′-cycloheptan\]-4-one (**7c**) {#sec4.9.3}

Purified by reverse phase C18 silica gel chromatography with H~2~O/MeCN (65/35) to give the product (130 mg, 0.53 mmol, 53% over two steps) as white solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 8.26 (br, 1H), 7.75 (d, *J* = 8.6 Hz, 1H), 6.51 (dd, *J* = 8.6, 2.2 Hz, 1H), 6.40 (d, *J* = 2.2 Hz, 1H), 2.70 (s, 2H), 2.09--2.03 (m, 2H), 1.77--1.61 (m, 6H), 1.57--1.50 (m, 2H), 1.43--1.36 (m, 2H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 193.1, 164.6, 162.5, 128.9, 114.3, 110.2, 103.9, 84.7, 48.5, 38.4, 29.4, 22.1. HRMS calculated for C~15~H~18~O~3~ (M -- H)^−^ 245.1183, found (M -- H)^−^ 245.1154. HPLC purity: 97.4% (254 nm), *t*~R~ = 6.67 min; 97.0% (220 nm), *t*~R~ = 6.67 min.

General Procedure for the Synthesis of **8a**--**h** {#sec4.10}
----------------------------------------------------

To a solution of corresponding acetophenone (1 mmol) and appropriate benzaldehyde (1.5 mmol) in methanol (10 mL) was added 60% KOH aqueous solution (1.5 mL) dropwise at room temperature. The resulting solution was stirred for 60 h at room temperature, after which the reaction mixture was neutralized with 10% HCl aq and extracted with ethyl acetate twice. The organic layer was washed with water, brine and dried over Na~2~SO~4~. The solvent was removed under reduced pressure, and the residue was dissolved in methanol (14 mL), followed by the careful addition of concentrated HCl (340 μL, 4 mmol). The obtained mixture was stirred at room temperature until the MOM-protected chalcone was gone, and then the mixture was concentrated. The crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc to afford the chalcones.

### (*E*)-3-(2-(Allyloxy)phenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (**8a**) {#sec4.10.1}

Purified with hexane/EtOAc (90/10) to give the product (175 mg, 0.59 mmol, 59% over two steps) as yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 13.49 (s, 1H), 8.18 (d, *J* = 15.6 Hz, 1H), 7.81 (d, *J* = 9.4 Hz, 1H), 7.74 (d, *J* = 15.6 Hz, 1H), 7.62 (d, *J* = 7.6 Hz, 1H), 7.36 (t, *J* = 8.4 Hz, 1H), 7.0 (t, *J* = 7.5 Hz, 1H), 6.94 (d, *J* = 8.4 Hz, 1H), 6.43--6.41 (m, 2H), 6.22 (s, 1H), 6.16--6.09 (m, 1H), 5.47 (d, *J* = 17.2 Hz, 1H), 5.35 (d, *J* = 10.6 Hz, 1H), 4.65 (d, *J* = 5.3 Hz, 2H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 192.8, 166.5, 162.9, 158.1, 140.5, 133.0, 132.2, 132.0, 130.1, 124.2, 121.4, 121.2, 118.4, 114.8, 112.8, 107.9, 103.9, 69.5. HRMS calculated for C~18~H~16~O~4~ (M -- H)^−^ 295.0976, found (M -- H)^−^ 295.0955. HPLC purity: 100% (254 nm), *t*~R~ = 7.20 min; 99.9% (220 nm), *t*~R~ = 7.20 min.

### (*E*)-1-(2,4-Dihydroxyphenyl)-3-(2-(hexyloxy)phenyl)prop-2-en-1-one (**8b**) {#sec4.10.2}

Purified by reverse phase C18 silica gel chromatography with H~2~O/MeCN (43/57) to give the product (170 mg, 0.50 mmol, 50% over two steps) as yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 13.61 (s, 1H), 8.11 (d, *J* = 15.6 Hz, 1H), 7.81--7.77 (m, 2H), 7.57 (dd, *J* = 7.6, 1.2 Hz, 1H), 7.35 (t, *J* = 7.9 Hz, 1H), 6.99--6.92 (m, 3H), 6.45--6.43 (m, 2H), 4.08--4.04 (m, 2H), 1.93--1.86 (m, 2H), 1.56--1.49 (m, 2H), 1.39--1.32 (m, 4H), 0.92--0.88 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 193.0, 166.4, 163.2, 158.8, 141.1, 132.14, 132.06, 130.7, 123.8, 121.3, 120.7, 114.6, 112.3, 108.1, 103.8, 68.7, 31.7, 29.4, 26.1, 22.7, 14.1. HRMS calculated for C~21~H~24~O~4~ (M -- H)^−^ 339.1602, found (M -- H)^−^ 339.1550. HPLC purity: 99.6% (254 nm), *t*~R~ = 8.00 min; 98.9% (220 nm), *t*~R~ = 8.01 min.

### (*E*)-1-(2,4-Dihydroxyphenyl)-3-(2-(octyloxy)phenyl)prop-2-en-1-one (**8c**) {#sec4.10.3}

Purified by reverse phase C18 silica gel chromatography with H~2~O/MeCN (45/55) to give the product (195 mg, 0.53 mmol, 53% over two steps) as yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 13.64 (s, 1H), 8.12 (d, *J* = 15.6 Hz, 1H), 7.80 (s, 1H), 7.77 (d, *J* = 6.2 Hz, 1H), 7.57 (d, *J* = 7.5 Hz, 1H), 7.35 (t, *J* = 8.2 Hz, 1H), 7.14 (br, 1H), 6.97 (t, *J* = 7.5 Hz, 1H), 6.92 (d, *J* = 8.3 Hz, 1H), 6.46--6.44 (m, 2H), 4.06--4.03 (m, 2H), 1.92--1.85 (m, 2H), 1.55--1.48 (m, 2H), 1.39--1.27 (m, 8H), 0.88--0.85 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 193.0, 166.3, 163.3, 158.8, 141.1, 132.2, 132.1, 130.6, 123.8, 121.2, 120.7, 114.6, 112.3, 108.2, 103.8, 68.7, 31.9, 29.5, 29.4, 29.3, 26.4, 22.8, 14.2. HRMS calculated for C~23~H~28~O~4~ (M + H)^+^ 369.2060, found (M + H)^+^ 369.2057. HPLC purity: 99.5% (254 nm), *t*~R~ = 8.36 min; 99.4% (220 nm), *t*~R~ = 8.36 min.

### (*E*)-1-(2,4-Dihydroxyphenyl)-3-(4-(piperidin-1-yl)phenyl)prop-2-en-1-one (**8d**) {#sec4.10.4}

Purification was performed without chromatography because of the poor solubility of product. The crude solid was washed with small amount of methanol three times to give the product (210 mg, 0.65 mmol, 65% over two steps) as yellow solid. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ (ppm) 8.19 (d, *J* = 9.0 Hz, 1H), 7.98--7.92 (m, 3H), 7.77 (d, *J* = 15.4 Hz, 1H), 7.67 (br, 2H), 6.45 (dd, *J* = 8.9, 2.2 Hz, 1H), 6.33 (d, *J* = 2.2 Hz, 1H), 3.49--3.46 (m, 4H), 1.88 (br, 4H), 1.64 (br, 2H). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ (ppm) 191.7, 166.3, 165.8, 133.5, 131.0, 113.5, 108.8, 103.1, 24.0. HRMS calculated for C~20~H~21~NO~3~ (M -- H)^−^ 322.1449, found (M -- H)^−^ 322.1407. HPLC purity: 99.0% (254 nm), *t*~R~ = 5.99 min; 98.8% (220 nm), *t*~R~ = 5.98 min.

### (*E*)-3-(2-(Allyloxy)phenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one (**8e**) {#sec4.10.5}

Purified with hexane/EtOAc (70/30) to give the product (106 mg, 0.34 mmol, 34% over two steps) as yellow solid. ^1^H NMR (400 MHz, CD~3~OD): δ (ppm) 8.25 (d, *J* = 15.8 Hz, 1H), 8.10 (d, *J* = 15.8 Hz, 1H), 7.61 (dd, *J* = 7.7, 1.3 Hz, 1H), 7.34--7.30 (m, 1H), 7.0--6.94 (m, 2H), 6.16--6.09 (m, 1H), 5.86 (s, 2H), 5.45 (dd, *J* = 17.3, 1.6 Hz, 1H), 5.29 (dd, *J* = 10.6, 1.4 Hz, 1H), 4.63 (d, *J* = 5.2 Hz, 2H). ^13^C NMR (100 MHz, CD~3~OD): δ (ppm) 194.5, 166.4, 166.1, 158.9, 138.2, 134.6, 132.4, 129.5, 129.1, 126.0, 122.0, 117.8, 113.9, 106.0, 96.0, 70.3. HRMS calculated for C~18~H~16~O~5~ (M -- H)^−^ 311.0925, found (M -- H)^−^ 311.0877. HPLC purity: 97.5% (254 nm), *t*~R~ = 6.93 min; 97.2% (220 nm), *t*~R~ = 6.93 min.

### (*E*)-3-(2-(Allyloxy)phenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (**8f**) {#sec4.10.6}

Purified with hexane/EtOAc (80/20) to give the product (205 mg, 0.73 mmol, 73% over two steps) as pale yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 8.42 (br, 1H), 8.16 (d, *J* = 15.8 Hz, 1H), 8.01--7.99 (m, 2H), 7.70 (d, *J* = 15.8 Hz, 1H), 7.61 (dd, *J* = 7.7, 1.4 Hz, 1H), 7.36--7.31 (m, 1H), 7.03--6.96 (m, 3H), 6.91 (d, *J* = 8.3 Hz, 1H), 6.11--6.02 (m, 1H), 5.43 (dd, *J* = 17.2, 1.4 Hz, 1H), 5.29 (dd, *J* = 10.6, 1.3 Hz, 1H), 4.61--4.59 (m, 2H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 190.8, 161.6, 158.0, 140.6, 132.9, 131.8, 131.5, 130.5, 129.6, 124.3, 122.8, 121.1, 118.1, 115.9, 112.7, 69.3. HRMS calculated for C~18~H~16~O~3~ (M -- H)^−^ 279.1027, found (M -- H)^−^ 279.0988. HPLC purity: 99.6% (254 nm), *t*~R~ = 6.99 min; 99.8% (220 nm), *t*~R~ = 6.99 min.

### (*E*)-3-(3-(Allyloxy)phenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (**8g**) {#sec4.10.7}

Purified with hexane/EtOAc (90/10) to give the product (113 mg, 0.38 mmol, 38% over two steps) as yellow solid. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ (ppm) 13.40 (s, 1H), 10.77 (br, 1H), 8.23 (d, *J* = 9.0 Hz, 1H), 7.98 (d, *J* = 15.4 Hz, 1H), 7.76 (d, *J* = 15.4 Hz, 1H), 7.53 (s, 1H), 7.43 (d, *J* = 7.6 Hz, 1H), 7.37 (t, *J* = 7.7 Hz, 1H), 7.05 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.43 (dd, *J* = 8.9, 2.3 Hz, 1H), 6.30 (d, *J* = 2.2 Hz, 1H), 6.11--6.03 (m, 1H), 5.44 (dd, *J* = 17.3, 1.4 Hz, 1H), 5.29 (d, *J* = 10.5 Hz, 1H), 4.65 (d, *J* = 5.2 Hz, 2H). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ (ppm) 191.5, 165.9, 165.3, 158.6, 143.7, 136.0, 133.6, 133.3, 130.0, 122.2, 121.5, 117.7, 117.4, 114.1, 113.0, 108.3, 102.6, 68.4. HRMS calculated for C~18~H~16~O~4~ (M + H)^+^ 297.1121, found (M + H)^+^ 297.1107. HPLC purity: 99.7% (254 nm), *t*~R~ = 7.22 min; 99.6% (220 nm), *t*~R~ = 7.22 min.

### (*E*)-3-(4-(Allyloxy)phenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (**8h**) {#sec4.10.8}

Purified with hexane/EtOAc (90/10) to give the product (130 mg, 0.44 mmol, 44% over two steps) as yellow solid. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ (ppm) 13.54 (s, 1H), 10.70 (br, 1H), 8.19 (d, *J* = 9.0 Hz, 1H), 7.87--7.75 (m, 4H), 7.04 (d, *J* = 8.7 Hz, 2H), 6.41 (dd, *J* = 8.9, 2.3 Hz, 1H), 6.29 (d, *J* = 2.3 Hz, 1H), 6.10--6.01 (m, 1H), 5.42 (dd, *J* = 17.3, 1.4 Hz, 1H), 5.28 (d, *J* = 10.5 Hz, 1H), 4.65 (d, *J* = 5.2 Hz, 2H). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ (ppm) 191.5, 165.8, 165.1, 160.4, 143.7, 133.4, 133.0, 131.0, 127.4, 118.6, 117.8, 115.1, 113.0, 108.2, 102.6, 68.4. HRMS calculated for C~18~H~16~O~4~ (M + H)^+^ 297.1121, found (M + H)^+^ 297.1108. HPLC purity: 99.8% (254 nm), *t*~R~ = 7.18 min; 99.6% (220 nm), *t*~R~ = 7.18 min.

General Procedure for the Synthesis of **8i**--**m** {#sec4.11}
----------------------------------------------------

The obtained appropriate chalcone (0.2 mmol) was dissolved in ethanol (2.5 mL) with a catalytic amount of concentrated HCl and then heated at 150 °C under microwave irradiation for 1.5 h. The solvent was removed under reduced pressure and the crude material was adsorbed onto silica gel and subjected to silica gel chromatography with hexane/EtOAc to afford the corresponding flavanones.

### 2-(2-(Allyloxy)phenyl)-7-hydroxychroman-4-one (**8i**) {#sec4.11.1}

Purified with hexane/EtOAc (90/10) to give the product (30 mg, 0.1 mmol, 50%) as pale yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.85 (d, *J* = 8.7 Hz, 1H), 7.60 (d, *J* = 7.6 Hz, 1H), 7.54 (br, 1H), 7.30 (t, *J* = 8.5 Hz, 1H), 7.04 (t, *J* = 7.5 Hz, 1H), 6.89 (d, *J* = 8.3 Hz, 1H), 6.58 (dd, *J* = 8.7, 2.2 Hz, 1H), 6.51 (d, *J* = 2.1 Hz, 1H), 6.03--5.95 (m, 1H), 5.87 (dd, *J* = 11.3, 5.0 Hz, 1H), 5.34 (d, *J* = 17.2 Hz, 1H), 5.24 (d, *J* = 10.6 Hz, 1H), 4.61--4.51 (m, 2H), 2.97--2.86 (m, 2H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 192.6, 164.5, 163.9, 154.9, 133.0, 129.6, 129.5, 127.8, 126.7, 121.2, 117.8, 114.8, 112.0, 111.0, 103.6, 75.0, 69.0, 43.4. HRMS calculated for C~18~H~16~O~4~ (M -- H)^−^ 295.0976, found (M -- H)^−^ 295.0949. HPLC purity: 98.0% (254 nm), *t*~R~ = 6.76 min; 99.0% (220 nm), *t*~R~ = 6.76 min.

### 2-(2-(Hexyloxy)phenyl)-7-hydroxychroman-4-one (**8j**) {#sec4.11.2}

Purified by reverse phase C18 silica gel chromatography with H~2~O/MeCN (50/50) to give the product (35 mg, 0.1 mmol, 52%) as pale yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.86 (d, *J* = 8.7 Hz, 1H), 7.58 (d, *J* = 7.6 Hz, 1H), 7.31 (t, *J* = 8.5 Hz, 1H), 7.02 (t, *J* = 7.5 Hz, 1H), 6.89 (d, *J* = 8.2 Hz, 1H), 6.59 (dd, *J* = 8.7, 2.2 Hz, 1H), 6.52 (d, *J* = 2.1 Hz, 1H), 5.86--5.82 (m, 1H), 4.03--3.93 (m, 2H), 2.96--2.87 (m, 2H), 1.79--1.72 (m, 2H), 1.45--1.37 (m, 2H), 1.31--1.27 (m, 4H), 0.87--0.84 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 192.8, 164.5, 164.1, 155.5, 129.52, 129.50, 127.5, 126.5, 120.7, 114.7, 111.5, 111.0, 103.6, 75.1, 68.3, 43.3, 31.6, 29.2, 25.9, 22.6, 14.1. HRMS calculated for C~21~H~24~O~4~ (M -- H)^−^ 339.1602, found (M -- H)^−^ 339.1563. HPLC purity: 99.9% (254 nm), *t*~R~ = 7.65 min; 99.6% (220 nm), *t*~R~ = 7.65 min.

### 7-Hydroxy-2-(2-(octyloxy)phenyl)chroman-4-one (**8k**) {#sec4.11.3}

Purified by reverse phase C18 silica gel chromatography with H~2~O/MeCN (42/58) to give the product (37 mg, 0.1 mmol, 50%) as pale yellow solid. ^1^H NMR (400 MHz, CDCl~3~): δ (ppm) 7.86 (d, *J* = 8.7 Hz, 1H), 7.58 (dd, *J* = 7.5, 1.0 Hz, 1H), 7.31 (t, *J* = 7.8 Hz, 1H), 7.02 (t, *J* = 7.5 Hz, 1H), 6.89 (d, *J* = 8.2 Hz, 1H), 6.60 (dd, *J* = 8.7, 2.2 Hz, 1H), 6.53 (d, *J* = 2.2 Hz, 1H), 5.86--5.82 (m, 1H), 4.03--3.93 (m, 2H), 2.97--2.87 (m, 2H), 1.79--1.72 (m, 2H), 1.44--1.37 (m, 2H), 1.32--1.24 (m, 8H), 0.87--0.83 (m, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ (ppm) 192.9, 164.6, 164.2, 155.5, 129.53, 129.49, 127.5, 126.5, 120.7, 114.6, 111.5, 111.0, 103.6, 75.1, 68.3, 43.3, 31.9, 29.4, 29.3, 29.2, 26.2, 22.7, 14.2. HRMS calculated for C~23~H~28~O~4~ (M + H)^+^ 369.2060, found (M + H)^+^ 369.2056. HPLC purity: 99.9% (254 nm), *t*~R~ = 8.05 min; 99.9% (220 nm), *t*~R~ = 8.05 min.

### 7-Hydroxy-2-(4-(piperidin-1-yl)phenyl)chroman-4-one (**8l**) {#sec4.11.4}

Purified with hexane/EtOAc (84/16) to give the product (37 mg, 0.11 mmol, 57%) as pale yellow solid. ^1^H NMR (400 MHz, CD~3~OD): δ (ppm) 7.73 (d, *J* = 8.7 Hz, 1H), 7.37--7.35 (m, 2H), 7.02--6.99 (m, 2H), 6.50 (dd, *J* = 8.7, 2.2 Hz, 1H), 6.36 (d, *J* = 2.2 Hz, 1H), 5.39 (dd, *J* = 12.9, 2.9 Hz, 1H), 3.19--3.16 (m, 4H), 3.06 (dd, *J* = 16.9, 12.9 Hz, 1H), 2.70 (dd, *J* = 16.9, 3.0 Hz, 1H), 1.75--1.69 (m, 4H), 1.63--1.59 (m, 2H). ^13^C NMR (100 MHz, CD~3~OD): δ (ppm) 193.6, 166.8, 165.6, 153.8, 131.2, 129.9, 128.5, 117.7, 115.1, 115.0, 111.7, 103.8, 81.0, 51.9, 44.8, 26.8, 25.4. HRMS calculated for C~20~H~21~NO~3~ (M -- H)^−^ 322.1449, found (M -- H)^−^ 322.1401. HPLC purity: 97.4% (254 nm), *t*~R~ = 5.22 min; 98.7% (220 nm), *t*~R~ = 5.22 min.

### 2-(2-(Allyloxy)phenyl)-5,7-dihydroxychroman-4-one (**8m**) {#sec4.11.5}

Purified with hexane/EtOAc (85/15) to give the product (47 mg, 0.15 mmol, 75%) as white solid. ^1^H NMR (400 MHz, CD~3~OD): δ (ppm) 7.54 (d, *J* = 7.6 Hz, 1H), 7.30 (td, *J* = 7.9, 1.6 Hz, 1H), 7.03--6.99 (m, 2H), 6.11--6.01 (m, 1H), 5.95 (d, *J* = 2.1 Hz, 1H), 5.90 (d, *J* = 2.1 Hz, 1H), 5.73 (dd, *J* = 12.7, 3.2 Hz, 1H), 5.38 (dd, *J* = 17.3, 1.6 Hz, 1H), 5.25 (dd, *J* = 10.6, 1.4 Hz, 1H), 4.65--4.56 (m, 2H), 2.99--2.91 (m, 1H), 2.83--2.78 (m, 1H). ^13^C NMR (100 MHz, CD~3~OD): δ (ppm) 197.7, 168.3, 165.5, 165.0, 156.4, 134.6, 130.5, 128.8, 127.5, 122.0, 117.6, 113.2, 103.3, 97.2, 96.2, 75.7, 70.0, 43.1. HRMS calculated for C~18~H~16~O~5~ (M -- H)^−^ 311.0925, found (M -- H)^−^ 311.0877. HPLC purity: 99.8% (254 nm), *t*~R~ = 7.14 min; 99.6% (220 nm), *t*~R~ = 7.14 min.

MIC Determination {#sec4.12}
-----------------

MIC values were determined against *M. tuberculosis* (H37Rv) and other bacteria using the standard microbroth dilution method exactly as previously described,^[@ref71]^ which is based on the methods by the Clinical and Laboratory Standards Institute.^[@ref72],[@ref73]^ The maximum test concentration used was 200 μg/mL.

Cytotoxicity Assays {#sec4.13}
-------------------

Cytotoxicity was assessed in vitro using Vero cells (kidney epithelial cells, ATCC CCL-81) as described previously.^[@ref74]^ In brief, monolayers of cells cultured in Dulbecco's modified Eagle medium (DMEM)/10% fetal bovine serum (FBS) were trypsinized, seeded at approximately 10% confluence in white-walled 96-well plates, and incubated overnight to allow adherence. Medium was replaced with DMEM/FBS containing 2-fold serial dilutions of test compounds. Detection was performed using MTT (CellTiter96, Promega) with overnight solubilization according to the manufacturer's instructions.

Approximation of Solubility in Cell Culture Media {#sec4.14}
-------------------------------------------------

The 2-fold serial dilutions in clear, round-bottom 96-well plates were prepared in DMEM with 5% FBS. Plates were incubated at 37 °C overnight. The highest compound concentration that did not result in visible precipitation of compound was used to approximate the solubility limit in cell culture medium.

Time Kill Experiments {#sec4.15}
---------------------

The ability of compounds to kill *S. aureus* Newman was evaluated using standard approaches.^[@ref75]^ Overnight cultures were diluted 1:25 in fresh Mueller--Hinton broth and grown to OD~600nm~ ≈ 0.3 before being exposed to compounds at various increments of their MICs. The number of viable bacteria over time was then determined.

Macromolecular Synthesis {#sec4.16}
------------------------

The effects of compounds on key macromolecular processes were determined as described,^[@ref76]^ using radiolabeled precursors from American Radiolabeled Chemicals, Inc.: \[methyl-^3^H\]thymidine, \[5,6-^3^H\]uridine, and \[4,5-^3^H\]leucine for DNA, RNA, and protein, respectively. Experiments were performed on three independent mid-logarithmic cultures (OD~600nm~ ≈ 0.3). The antibiotics ciprofloxacin (DNA, from Sigma-Aldrich), rifampicin (RNA, from TCI America), and erythromycin (protein, from Calbiochem) were used as positive controls.

Analysis of the Membrane Potential {#sec4.17}
----------------------------------

The effects of compounds on the membrane potential of *S. aureus* were evaluated by flow cytometry using the fluorescent probe diethyloxacarbocyanine dye DiOC~2~(3). The emission of red fluorescence of DiOC~2~(3) from cells is dependent on the membrane potential, while green fluorescence emission is independent of the membrane potential. Therefore, the ratio of red to green fluorescence provides a measure of the effects of compounds on the membrane potential. These experiments were performed as previously described,^[@ref76]^ using *S. aureus* Newman grown to OD~600nm~ ≈ 0.3 in Mueller--Hinton II. Samples were analyzed using BD LSR II flow cytometer and the effects of compounds on the membrane potential evaluated using the software FlowJo X 10.0.7 as described.^[@ref76]^ Carbonyl cyanide *m*-chlorophenylhydrazone (CCCP; Sigma-Aldrich) and vancomycin were used as positive and negative controls, respectively.

Assay of Relaxation Activity of *E. coli* Topoisomerase I {#sec4.18}
---------------------------------------------------------

Recombinant *E. coli* topoisomerase I (EcTopI) was purified with published procedures.^[@ref77]^ CsCl gradient purified plasmid DNA (160 ng) was added to relaxation reaction buffer containing 10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 0.1 mg/mL gelatin, and 0.5 mM MgCl~2~. The resulting solution was divided into 9.5 μL aliquots, to which 0.5 μL of the 20 mM compounds dissolved in DMSO was added for final compound concentrations of 500 μM. The compound control reaction received only DMSO. EcTopI (20 ng) in 10 μL of the relaxation reaction buffer was then added to each DNA/compound reaction mixture. The reaction mixtures were then incubated at 37 °C for 30 min before the reaction was terminated, and the mixtures were loaded onto a 1% agarose gel for electrophoretic analysis in TAE buffer (40 mM Tris--acetate, pH 8.1, 2 mM EDTA) as described previously.^[@ref78]^

*E. coli* DNA Gyrase Supercoiling Assay {#sec4.19}
---------------------------------------

The *E. coli* DNA gyrase supercoiling assay was performed according to the manufacturer's protocol. Briefly, 1.25 U of *E. coli* DNA gyrase (New England Biolabs) was added to 20 μL of DNA gyrase reaction mixture (35 mM Tris-HCl, pH 7.5, 24 mM KCl, 4 mM MgCl~2~, 2 mM DTT, 1.75 mM ATP, 5 mM spermidine, 0.1 mg/mL BSA, 6.5% glycerol) containing 300 ng of relaxed plasmid DNA substrate (New England Biolabs) in the presence of indicated concentration of compound. After incubation at 37 °C for 30 min, the reactions were stopped and analyzed by agarose gel electrophoresis similarly as the topoisomerase I relaxation assay.^[@ref78]^ IC~50~ values (compound concentrations at which only 50% of the input DNA was converted to supercoiled form) were calculated by spot densitometry analysis with AlphaView, AlphaImager Mini (Protein Simple). The IC~50~ values represent the average from at least two experiments performed separately.

*E. coli* Topoisomerase IV Decatenation Assay {#sec4.20}
---------------------------------------------

For the assay of decatenation activity of topoisomerase IV,^[@ref79]^ 0.25 U of *E. coli* topoisomerase IV (Topogen) was added to 20 μL of decatenation reaction mixture (40 mM HEPES-KOH, pH 8.0, 100 mM potassium glutamate, 10 mM magnesium acetate, 10 mM dithiothreitol, 50 μg of BSA/mL) containing 290 ng of kinetoplast DNA substrate (Topogen) and 1 mM ATP in the presence of indicated concentration of compound. After incubation at 37 °C for 30 min, the reactions were stopped by the addition of stop buffer (50 mM EDTA, 50% glycerol, and 0.5% (v/v) bromophenol blue). The DNA samples were electrophoresed in a 1% agarose gel containing 0.5 μg/mL ethidium bromide in TAE buffer also containing 0.5 μg/mL ethidium bromide. Visualization of the bands was carried out by exposure to UV light. IC~50~ values (compound concentrations at which only 50% of kinetoplast DNA was converted into monomeric products) were calculated by spot densitometry analysis with AlphaView, AlphaImager Mini (Protein Simple). The IC~50~ values represent the average from at least two experiments performed separately.

NMR and HRMS spectra and HPLC profiles of all synthetic compounds; ORTEP views of **3g** and **8a**; inhibition data. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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